Journal articles on the topic '331.256 8'
To see the other types of publications on this topic, follow the link: 331.256 8.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic '331.256 8.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
von Schenck, H., L. Treichl, B. Tilling, and A. G. Olsson. "Laboratory and field evaluation of three desktop instruments for assay of cholesterol and triglyceride." Clinical Chemistry 33, no. 7 (July 1, 1987): 1230–32. http://dx.doi.org/10.1093/clinchem/33.7.1230.
Abstract:
Abstract We evaluated three desktop instruments suitable for decentralizing the assays of blood cholesterol and triglycerides to satellite and physician's office testing. The instruments, Ektachem DT 60 (E), Reflotron (R), and Seralyzer (S), were used according to their manufacturers' instructions to assay serum or capillary blood from outpatients at two physicians offices. Accuracy was assessed in the centralized laboratory by using an automated centrifugal analyzer (A). The bias of A was monitored with an international quality-control material. We found all instruments easy to handle. Regression equations for cholesterol determinations were: E = 0.92A + 0.7 (n = 331, r = 0.94), R (capillary blood) = 0.96A + 0.3 (n = 256, r = 0.95), and S = 0.93A + 0.6 (n = 260, r = 0.92). For triglycerides we obtained E = 1.02A (n = 331, r = 0.97), R (cap. blood) = 0.88A (n = 213, r = 0.97), R = 0.94A + 0.1 (n = 90, r = 0.99), and S = 0.96A (n = 266, r = 0.98). Duplicate and within-day precision was less than 8%. Between-day precision (during a month) was less than 10%. We stress the need of both laboratory and field evaluation and emphasize the benefit of quality control.
2
Feinsilber, Doron, Cliff Whatcott, Marc Ryan Matrana, John T. Cole, Ruben Munoz, Qingyang Luo, Jyotsna Fuloria, and Suma Satti. "In vitro synergistic cellular proliferation inhibition in pancreatic cancer cells Su86 and Mia-PaCa-2 with fluvastatin and nab-paclitaxel." Journal of Clinical Oncology 33, no. 3_suppl (January 20, 2015): 331. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.331.
Abstract:
331 Background: Statins have been shown to possess antiproliferative activity in-vitro. Synergism with multiple drug combinations has been of great interest in pancreatic cancer. We examined 2 in-vitro cell models for synergism using a combination of fluvastatin and nab-paclitaxel. Methods: Pancreatic cancer cell lines Mia-Paca-2 (MP2) and Su86 were cultivated and seeded to 25,000 cells/mL and subsequently grown in 96 well plates for 24 hours. The cells were then treated with a fixed concentration of fluvastatin in 9 rows, 8 receiving serial 1:2 dilutions 16 times in triplicate of nab-paclitaxel, 1 fluvastatin only row, and 1 untreated. Upon dosing cells were incubated for 72 hrs. Cellular proliferation was determined by sulforhodamine B proliferation assays and read at 570 nm. A nab-paclitaxel only assay was done as well for comparison. Results: The lowest inhibitory concentration of fluvastatin in combination with nab-paclitaxel was between 500-600 micro mole (mm). Fluvastatin alone at these concentrations attenuated cellular proliferation. Synergism was seen on IC50 curves that are available. Anti-proliferative effects were reduced by 1:256 dilution. Conclusions: Preliminary studies show fluvastatin has an in-vitro anti proliferative effect on Su86 and MP2 cells and synergism in combination with nab-paclitaxel. Fluvastatin is more cytotoxic in Su86 than MP2. Future experimental design will focus on in-vivo models.
3
Meggendorfer, Manja, Tamara Alpermann, Torsten Haferlach, Carina Schrauder, Rabea Konietschke, Claudia Haferlach, Wolfgang Kern, and Susanne Schnittger. "Mutational Screening Of CSF3R, ASXL1, SETBP1, and SRSF2 In Chronic Neutrophilic Leukemia (CNL), Atypical CML and CMML Cases." Blood 122, no. 21 (November 15, 2013): 105. http://dx.doi.org/10.1182/blood.v122.21.105.105.
Abstract:
Abstract Introduction Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are rare myeloproliferative and myelodysplastic/myeloproliferative neoplasms. So far, the diagnosis of CNL and aCML has been based on cytomorphology and the absence of JAK2V617F and PDGFR rearrangements. Recently, mutations in CSF3R and SETBP1 were identified and associated with CNL and aCML, respectively. Chronic myelomonocytic leukemia (CMML) and aCML also share several characteristics and need to be discriminated especially by the absolute number of monocytes in the peripheral blood. Aim To determine the frequency of CSF3R mutations (CSF3Rmut) in CNL, aCML, and CMML and to investigate a mutation pattern, cytogenetics and clinical data in all three entities. Patients and Methods To first delineate patients with potential CNL, we investigated blood and bone marrow smears and depicted patients with a white blood cell count >25x109/L, neutrophils >80%, immature granulocytes <10%, <1% myeloblasts and hypercellular bone marrow (according to WHO 2008). BCR-ABL1 fusion transcript, JAK2 and MPL mutations were excluded in all cases by RT-PCR and melting curve analyses. Indication for PDGFR rearrangements was precluded by over-expression analyses of PDGFRA and PDGFRB by quantitative real-time PCR, resulting in a final cohort of 20 cases declared as CNL patients. Additional 60 aCML and 252 CMML patients were included. Cytogenetics was available in 330/332 cases. Mutations in CSF3R exons 14 and 17 (n=332), in ASXL1 exon 13 (n=321), and the mutational hot spots in SETBP1 (n=331) and SRSF2 (n=320) were analyzed by Sanger sequencing. Results In the total cohort of 332 patients we detected CSF3R mutations in 11 cases (3.3%). 8/11 cases showed a p.Thr618Ile mutation in exon 14, four of them carried an additional nonsense/frame-shift mutation in exon 17. One additional patient was mutated in p.Thr615Ala and showed a nonsense mutation in exon 17. Two cases showed a mutation in exon 17 only, one a nonsense the other a frame-shift mutation, respectively. Analyzing the mutation frequencies within the different entities revealed a clustering of CSF3Rmut within CNL cases with 7 of 20 (35%) mutated cases in contrast to 2 of 60 (3.3%; p=0.001) aCML and 2 of 252 (0.8%; p<0.001) CMML cases. Cytogenetics in CSF3Rmut cases showed that 9/11 cases had a normal karyotype and only one aCML patient harbored a del(3q) and one CMML patient a complex karyotype. Mutations in the three other analyzed genes ASXL1, SETBP1 and SRSF2 were detected in the total cohort in 156/321 (49%), 34/331 (10%), and 149/330 (45%) patients, respectively. Analyses regarding concomitant mutations of CSF3R with ASXL1, SETBP1 or SRSF2 revealed no additional mutation in two cases. In 8 of 11 parallel analyzed CSF3Rmut patients an ASXL1mut was identified, SETBP1 as well as SRSF2 were mutated in 3 of the 11 cases. Notably, the 7 CSF3Rmut within the CNL group had no mutation in SETBP1. Analysis of mutational loads in CNL showed that 6/7 CSF3Rmut had a higher mutational load than the second mutated gene (range: 25-50% vs. 10-30%). In one case both mutated genes had equal mutational loads (40%). In contrast, in CMML and aCML 3/4 patients had lower mutational loads in CSF3Rmut than in the additional mutated genes (20-50% vs. 40-50%), while also one case showed equal mutational loads in the mutated genes (50%). Combining the mutational results of these four genes indicate a specific and individual molecular pattern for these three different entities. While ASXL1 is frequently mutated in all entities (CNL: 8/11 (73%); aCML: 38/59 (64%); CMML: 110/251 (44%)), SRSF2 shows the highest mutation frequency in CMML cases (121/251; 48%), followed by aCML (24/60; 40%) and CNL (4/19; 21%). In contrast, SETBP1 is often mutated in aCML (19/60; 32%) and rarely in CMML (13/252; 5%) and CNL (2/19; 10.5%) patients. In addition, CSF3R is much more associated with the CNL cases (35%) and less frequently found in aCML (2%) and CMML (1%). Conclusion 1) CNL, aCML and CMML are related diseases and difficult to distinguish by cytomorphology alone and therefore require additional diagnostic criteria, i.e. molecular mutations. 2) ASXL1 is the most frequently mutated gene in these entities and thus can help to prove clonality. 3) SETBP1 much more closely relates to aCML and SRSF2 to CMML. 4) Mutations in the novel marker CSF3R are closely related to CNL and thus qualify as a new molecular marker for diagnosis of CNL. Disclosures: Meggendorfer: MLL Munich Leukemia Laboratory: Employment. Alpermann:MLL Munich Leukemia Laboratory: Employment. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Schrauder:MLL Munich Leukemia Laboratory: Employment. Konietschke:MLL Munich Leukemia Laboratory: Employment. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Kern:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Schnittger:MLL Munich Leukemia Laboratory: Employment, Equity Ownership.
4
Blissett, Donovan J. "Slope engineering for mountain roads, edited by G. J.Hearn. Geological Society Engineering Geology Special Publication, 24, London, 2011. No. of pages: xiii + 301. Price: UK£90.00. ISBN 978-1-86239-331-8 (hardback)." Geological Journal 49, no. 6 (April 29, 2014): 657. http://dx.doi.org/10.1002/gj.2565.
5
Yazdani, H., H. Rahmani, M. Edris, and E. Dirandeh. "158. EFFECT OF A59V LOCUS IN THE LEPTIN GENE ON LENGTH OF PREGNANCY IN IRANIAN HOLSTEIN COWS." Reproduction, Fertility and Development 21, no. 9 (2009): 76. http://dx.doi.org/10.1071/srb09abs158.
Abstract:
We investigated effect of A59V polymorphism in the leptin gene on length of pregnancy. Blood was collected from 255 Holstein cattles belonging to four different herd managements in Isfahan province. Genomic DNA extracted from whole blood. Genotypes of A59V locus were identified PCR-RFLP technique. Amplified region is located in exon three of leptin gene. The genomic bovine leptin sequences, which consist of three exons, were obtained from Gene Bank (Accession number U50365). The polymerase chain reaction was used to amplify the 331 bp DNA fragments from genomic DNA. The PCR reaction contained 100 ng of genomic DNA, 0.3 µM of each primer, 1.5 mM MgCl2, 200 µM dNTP, 10mM Tris HCl, 50 mM KCl and 1 U Taq-polymerase in total volume of 20 µL. Sequences of primers that were used in PCR were reported previously by Haegeman et al. (2000). Conditions for PCR were 94°C for 2 min, followed by 35 cycles of 94°C for 30 s, 55°C for 1 min, and 72°C for 30 s. Followed by final extension for at for 15 min 72°C. Digestion of PCR product of 331 bp with 5 U of HphI (Fermentas) in 20 µL of reaction volume at 37°c for 8 h and analyzed on 8% no denature polyacrylamyde gel. Allele A in the A59V locus was the allele not digested by restriction enzyme, allele B was the restriction enzyme-digested PCR product. Digestion revealed 3 genotypes, AA (331 bp), AB (331, 311, and 20 bp), and BB (311 and 20 bp). Significances of the genotype effects were estimated by GLM procedure of SAS. This study showed that genotype effect on length of pregnancy were significant (P<0.01). Animals homozygous for allele A had higher length of pregnancy ((P<0.01, AA=279.17±0.47, AB=276.96±0.57, BB=274.8±2.2).
6
Shivaprakash, H. S., Manorama Tripathy, J. Sreenivasamurthy, and Manu V. Devadevan. "Book Reviews." Indian Theatre Journal 3, no. 1 (December 1, 2019): 57–65. http://dx.doi.org/10.1386/itj_00006_5.
Abstract:
Kannada Theatre History 1850–1950: A Sourcebook, K. V. Akshara (ed.), B. R. Venkataramana Aithala and Deepa Ganesh (2018)Manipal: Manipal University Press, 288 pp.,ISBN 978-93-82460-84-8, p/bk, Rs. 250Theatre of the Earth – The Works of Heisnam Kanhailal: Essays and Interviews, Heisnam Kanhailal (2016)Calcutta: Seagull Books, 235 pp.,ISBN 978-8-17046-353-5, p/bk, Rs. 450Shakespeare: Kannada Spandana (in Kannada), Nataraj Huliyar (ed.) (2016)Bangalore: Kuvempu Bhasha Bharati Pradhikara, 330 pp.,ISBN 555-1-23408-868-3, p/bk, Rs. 150Chathirangam (in Malayalam), Ashok D’Cruz (ed.), C. K. Namboothiri (2018)Tirur: Thunchath Ezhuthachan Malayalam University, 256 pp.,ISBN 978-8-19374-580-9, h/bk, Rs. 250
7
McGain, Forbes, Jason R. Bishop, Laura M. Elliot-Jones, David A. Story, and Georgina LL Imberger. "A survey of the choice of general anaesthetic agents in Australia and New Zealand." Anaesthesia and Intensive Care 47, no. 3 (May 2019): 235–41. http://dx.doi.org/10.1177/0310057x19836104.
Abstract:
Strategies to reduce the adverse environmental costs of anaesthesia include choice of agent and fresh gas flows. The current preferences of Australian and New Zealand anaesthetists are unknown. We conducted a survey of Australian and New Zealand anaesthetists to determine the use of volatiles, nitrous oxide and intravenous anaesthesia, lowest fresh gas flow rates, automated end-tidal volatile control, and the rationales for these choices. The survey was answered by 359/1000 (36%), although not all questions and multiple responses within single questions were answered by all respondents. Sevoflurane was preferred by 246/342 (72%, 95% confidence interval (CI) 67%–77%), followed by propofol, 54/340 (16%, 95% CI 12%–20%), desflurane 39/339 (12%, 95% CI 8%–16%) and isoflurane 3/338(1%, 95% CI 0–3%). When asked about all anaesthetics, low-risk clinical profile was the most common reason given for using sevoflurane (129/301 (43%, 95% CI 37%–49%)), reduced postoperative nausea for propofol (297/318 (93%, 95% CI 90%–96%)) and faster induction/awakening times for desflurane (46/313 (79%, 95% CI 74%–83%)). Two-thirds (226/340 (66%, 95% CI 61%–71%)) of respondents used nitrous oxide in 0–20% of general anaesthetics. Low fresh gas flow rates for sevoflurane were used by 310/333 (93%, 95% CI 90%–95%) and for 262/268 (98%, 95% CI 95%–99%) for desflurane. Automated end-tidal control was used by 196/333 (59%, 95% CI 53%–64%). The majority of respondents (>70%) preferred sevoflurane at low flows. These data allow anaesthetists to consider further whether changes are required to the choices of anaesthetic agents for environmental, financial, or any other reasons.
8
Cejudo, Antonio, Francisco Javier Robles-Palazón, Francisco Ayala, Mark De Ste Croix, Enrique Ortega-Toro, Fernando Santonja-Medina, and Pilar Sainz de Baranda. "Age-related differences in flexibility in soccer players 8–19 years old." PeerJ 7 (January 29, 2019): e6236. http://dx.doi.org/10.7717/peerj.6236.
Abstract:
Background Muscle flexibility is a main component of health-related fitness and one of the basic components of fitness for the performance in some sports. Sport and health professionals require the flexibility profile of soccer to define quantitative aims in the training of flexibility. The aim of this study was to identify age-related differences in lower extremity flexibility in youth soccer players. Methods Seventy-two young male soccer players (age: 13.0 ± 3.1 y; body mass: 50.5 ± 15.3 kg; stature 158.2 ± 16.8 cm; BMI: 19.6 ± 2.6 kg/m2) completed this study. Measures of eleven passive hip (hip extension (HE), hip adduction with hip flexed 90°(HAD-HF90°), hip flexion with knee flexed (HF-KF) and extended (HF-KE), hip abduction with hip neutral (HAB) and hip flexed 90°(HAB-HF90°), hip external (HER) and internal (HIR) rotation), knee (knee flexion (KF)) and ankle dorsiflexion (ankle dorsiflexion with knee flexed (ADF-KF) and extended (ADF-KE)) ranges of motion (ROM) were taken. Descriptive statistics were calculated for hip, knee and ankle ROM measured separately by leg (dominant and non-dominant) and age-group (U10, U12, U14, U16 and U19). The data was analysed using a one-way analysis of variance (ANOVA) to examine the interaction of 11 ROM in the different players’ age-group. Results Generally, U10 and/or U12 soccer players obtain the highest mean value in almost all ROM evaluated (U10: HAD-HF [39.6° ± 4.3°], ADF-KE [32.3° ± 4.1°], HER [63.5° ± 5.6°] and HAB-HF90°[64.1° ± 7.5°]; U12: HE [17.7° ± 6.2°], HAB [35.6° ± 3.0], HIR [60.8° ± 4.7°] and KF [133.8° ± 7.1°]). Nonetheless, significant differences between the players’ age-groups are just found in HAD-HF90°(p = .042; ES = .136), HAB (p = .001; ES = .252), HIR (p = .001; ES = .251), HER (p < .001; ES = .321) and HAB-HF90°(p < .001; ES = .376) ROM, showing a progressive and irregular decrease in these ROM until the U19 team. Conclusion The findings of this study reinforce the necessity of prescribing exercises aimed at improving HAD-HF90° ROM in U16, HAB ROM in U14, HIR ROM in U16 and U19, HER ROM in U12 and U19, and HAB-HF90° ROM in U16 and U19 players within everyday soccer training routines.
9
Purbajanti, Endang, Kusmiyati F, and Eny Fushkah. "Water use efficiency and nutrient uptake of rice under soil water stress condition." Jurnal Pertanian Tropik 7, no. 1 (April 6, 2020): 72–81. http://dx.doi.org/10.32734/jpt.v7i1.3732.
Abstract:
One obstacle that can limit the growth and production of rice is low water availability. Therefore, a comprehensive study of the response of rice plants to drought is very important. The study was conducted in the greenhouse of the Faculty of Animal Husbandry and Agriculture, Diponegoro University, from April to August 2016. The study used a 3 x 3 factorial design with 3 replications. The first factor is three types of rice (Sidenuk, Way Apo Buru, Pepe) and the second factor is water stress treatment (KA <field capacity = enough water, field capacity (KL), water saturation (JA). The observed parameters are protein content, leaf levels rolling (number of leaves rolled), relative water content (RWC), water use efficiency (WUE), N, P, K uptake, rice protein content decreases with increasing water supply. The relative water content of rice plants decreases with increasing stress water that occurs in the limited water supply for the three types of rice Sidenuk rice has the lowest N seed content (2.1%) compared to Way Apo (3.0%) and Pepe (3.1%). The mineral content of P in both biomass and seeds is not really influenced by water stress, as well as K content of seeds. REFERENCES Badan Pusat Statistik. 2018. https://www.bps.go.id/dynamictable/2019/04/15/1608/luas-panen-produksi-dan-produktivitas-padi-menurut-provinsi-2018.html Darwesh, R, S,S. 2013. Improving growth of date palm plantlets grown undersalt stress with yeast and amino acids applications Annals of Agricultural Science (2013) 58(2), 247–256 Etienne P.I.D, S. Diquelou , M. Prudent, C. Salon., A. Maillard, and A.Ourry. 2018. Macro and Micronutrient Storage in Plants and Their Remobilization When Facing Scarcity: The Case of Drought. Agriculture 2018, 8, 14; 2-17. doi:10.3390/agriculture8010014 Farooq, M., S.M.A.Basra, A. Wahid, Z.A.Cheema, M.A.Cheema, A.Khaliq. 2008. The physiological role of exogenously applied glycine betaine in improving drought tolerance of fine grain aromatic rice (Oryza sativa L.).Journal of Agronomy & Crop Science, 194: 325-333. Fitter, A.H.dan R.K.M. Hay. 1991. Fisiologi lingkungan tanaman. Gadjah Mada University Press, Yogyakarta Gholinezhad, E., A.Ayanaband, A. H. Ghorthapeh, G.Noormohamadi, I.Bernousi.2009. Study of the Effect of Drought Stress on Yield, Yield Components, and Harvest Index of Sunflower Hybrid Iroflor at Different Levels of Nitrogen and Plant Population. Not. Bot. Hort. Agrobot. Cluj 37 (2) 2009, 85-94 Kivuva, B.M. , S.M. Githiri, G. C. Yencho, J.Sibiya.2015. Screening sweet potato genotypes for tolerance to drought stress. Field Crops Research 171 (2015) 11–22 Jaleel CA, Manivannan P, Wahid A, Farooq M, Al-Juburi H J, Somasundaram R, Panneerselvam R. 2009. Drought stress in plants: A review of morphological characteristics and pigment composition. Int J Agric Biol, 11: 100–105. Nazar, R., S. Umar, N.A. Khan, O. Sareer. 2015. Salicylic acid supplementation improves photosynthesis and growth in mustard through changes in proline accumulation and ethylene formation under drought stress. South African Journal of Botany 98 (2015) 84–94. Nio, S.A. dan A.A. Lenak. 2014. Penggulungan daun pada tanaman monokotil saat kekurangan air. Journal Bio Logos, Agustus 2014, Vol.2, No 4: 48-55. Nuryani, S.H.U., Haji,M., Widya, N. Y., 2010. Serapan hara N,P,K pada tanaman padi dengan lama penggunaan pupuk organic pada vertisol Sragen. Jurnal Ilmu Tanah dan Lingkungan vul 10 No 1 : 1-13 Oh, M.W., and S. Komatsu. 2015. Characterization of proteins in soybean roots under flooding and drought stresses. Journal of Proteomics. 114 (2015): 161-181. Pandey, V., and A.Shukla.2015.Acclimation and Tolerance Strategies of Rice under Drought Stress. Rice Science, 2015, 22(4): 147-.161. Penny-packer, B. W., K. T. Leath., W. L. Stout, and R. R. Hill. 1990. Technique for stimulating field drought stress in the greenhouse. Agr. J. 82 (5): 951–957. Purbajanti, E.D., F. Kusmiyati, and E. Fuskhah. 2017. Growth, Yield, and Physiological Characters of Three Types of Indonesian Rice Under Limited Water Supply. Asian J. Plant Sci., 16 (2): 101-108, 2017. Shi, G., S. Xia., J. Ye, Y. Huang, C. Liu, Z. Zhang .2015. PEG-simulated drought stress decreases cadmium accumulation in castor bean by altering root morphology. Environmental and Experimental Botany 111 (2015) 127–134. Shao H B, L.Y.Chu, M.A. Shao, C.A.Jaleel, H.M. Mi. 2008. Higher plant antioxidants and redox signaling under environmental stresses. Comp Rend Biol, 331: 433–441. Steel, R.G.D., and J.H. Torrie, 1960. Principles and Procedures of Statistics. McGraw-Hill, New York, USA. Suryanti, S., D. Indradewa, P. Sudira, J. Widada. 2015. Water Use, Water Use Efficiency, and Drought Tolerance of Soybean Cultivars. AGRITECH, Vol. 35, No. 1, February 2015: 114-120. Wu,X. and W. Bao. 2011. Leaf Growth, Gas Exchange and Chlorophyll FluorescenceParameters in Response to Different Water Deficits in Wheat Cultivars. Plant Prod. Sci. 14(3): 254―259 (2011) Zhang, X., X. Chen, Z. Wu, X. Zhang, C. Huang and M. Cao, 2005. A dwarf wheat mutant is associated with increased drought resistance and altered responses to gravity. Afr. J. Biotechnol., 4: 1054-1057. Zou L., X.Sun, Z. Zhan, P. Li, J. Wu, Tian Cai-juan, Qiu Jin-long, Lu Tie-gang (2011) Leaf rolling controlled by the homeodomain leucine zipper class IV gene Roc5 in rice. Plant Physiology 156:1589– 1602
10
ศิริพันธุ์เมือง, ทิศากร, ภาวิณี แสนชนม์, รดาณัฐ ภูสมนึก, กันยามาศ สงวนศักดิ์, and เดือนเพ็ญ หัสขันธ์. "การสังเคราะห์วรรณกรรมแนวทางการพัฒนาศูนย์การเรียนรู้ชุมชน." Interdisciplinary Academic and Research Journal 4, no. 3 (May 23, 2024): 193–214. http://dx.doi.org/10.60027/iarj.2024.275062.
Abstract:
ภูมิหลังและวัตถุประสงค์: ศูนย์การเรียนรู้ชุมชน คือแหล่งเรียนรู้ของประชาชนในชุมชน ซึ่งเป็นศูนย์กลางของชุมชนในการรวบรวมข้อมูล ข่าวสาร องค์ความรู้ ภูมิปัญญา เพื่อส่งเสริม สนับสนุนการจัดการเรียนรู้ การถ่ายทอด แลกเปลี่ยนประสบการณ์ วัฒนธรรม ภูมิปัญญาท้องถิ่นและการจัดกิจกรรมต่าง ๆ ของประชาชนในชุมชน เกิดพฤติกรรมรักการค้นคว้าหาความรู้และเรียนรู้ด้วยตนเองตามความต้องการอย่างกว้างขวางและต่อเนื่อง ดังนั้นการสังเคราะห์วรรณกรรมแนวทางการพัฒนาศูนย์การเรียนรู้ชุมชนจึงเป็นประโยชน์ต่อชุมชนอย่างยิ่ง การวิจัยครั้งนี้มีวัตถุประสงค์เพื่อศึกษาคุณลักษณะงานวิจัยการพัฒนาศูนย์การเรียนรู้ชุมชน ประชากรที่ใช้ในการวิจัยได้แก่ งานวิจัยเกี่ยวกับแนวทางการพัฒนาศูนย์การเรียนรู้ชุมชนจากฐานข้อมูล TCI ที่เผยแพร่ตั้งแต่ปี พ.ศ. 2560 -2566 จำนวน 8 เรื่อง ขอบเขตด้านเนื้อหา สังเคราะห์คุณลักษณะ 3 ด้าน ได้แก่ วัตถุประสงค์งานวิจัย ระเบียบวิธีวิจัย แนวทางการพัฒนาศูนย์การเรียนรู้ชุมชน และสังเคราะห์เอกสารเกี่ยวกับการแนวทางพัฒนาศูนย์การเรียนรู้ชุมชน จำนวน 3 เล่ม โดยใช้คำค้นคือ ศูนย์การเรียนรู้ชุมชน แหล่งสารสนเทศชุมชน ผลการศึกษาวิจัย: (1) การพัฒนารูปแบบศูนย์การเรียนรู้ชุมชนมากที่สุด รองลงมาคือ แนวทางการบริหารจัดการศูนย์การเรียนรู้ชุมชน (2) การใช้วิธีวิจัยแบบผสมผสานวิธีวิจัยแบบผสมผสานมากที่สุด รองลงมาคือ ใช้วิธีวิจัยเชิงคุณภาพ และวิธีวิจัยเชิงพัฒนา (3). แนวทางการพัฒนาศูนย์การเรียนรู้ชุมชนได้แก่ แนวทางการพัฒนาศูนย์การเรียนรู้ชุมชนประกอบด้วย (3.1) ด้านการบริหารจัดการ (3.2) ด้านภาคีเครือข่ายความร่วมมือ (3.3) ด้านองค์ความรู้ (3.4) ด้านกิจกรรมการเรียนรู้ (3.5) ด้านการประชาสัมพันธ์ และ (3.6) ด้านเทคโนโลยีสารสนเทศ สรุปผล: ผลการศึกษาชี้ให้เห็นถึงการจัดลำดับความสำคัญของการทำความเข้าใจโมเดลขั้นสูงและแนวทางการจัดการสำหรับศูนย์การเรียนรู้ชุมชน ควบคู่ไปกับการเลือกวิธีการวิจัยแบบผสมผสาน โดยเฉพาะอย่างยิ่งแนวทางเชิงคุณภาพและการพัฒนา นอกจากนี้ แนวปฏิบัติในการพัฒนาศูนย์เน้นองค์ประกอบที่สำคัญ เช่น การจัดการที่มีประสิทธิภาพ ความร่วมมือกัน การเผยแพร่ความรู้ กิจกรรมการเรียนรู้ที่มีส่วนร่วม การประชาสัมพันธ์เชิงกลยุทธ์ และการใช้ประโยชน์จากเทคโนโลยีสารสนเทศ การค้นพบนี้นำเสนอข้อมูลเชิงลึกที่สำคัญสำหรับการปรับปรุงและการจัดตั้งศูนย์การเรียนรู้ชุมชน โดยมีเป้าหมายเพื่อเพิ่มผลกระทบและประสิทธิผลในการให้บริการชุมชน
11
Kang, Jihoon, Bumjun Kim, Changhoon Yoo, Jaewon Hyung, Kyu-Pyo Kim, Baek-Yeol Ryoo, and Heung-Moon Chang. "Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary cancer after failure of gemcitabine plus cisplatin: Retrospective analysis of 321 patients." Journal of Clinical Oncology 35, no. 4_suppl (February 1, 2017): 425. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.425.
Abstract:
425 Background: In advanced biliary tract cancer (BTC), the role of 2nd line chemotherapy after failure of 1st line gemcitabine plus cisplatin (GEMCIS) has not been established. Fluoropyrimidine(FP)-based regimens are widely used as 2nd line treatment in clinical practice. We retrospectively analyzed the efficacy of 2nd line FP-based chemotherapy in patients(pts) with advanced BTC after failure of GEMCIS. Methods: Histologically confirmed advanced BTC pts who received 1st line GEMCIS at Asan Medical Center between December 2010 and June 2016 were identified. Among 748 pts treated with GEMCIS, 331 patients (44%) subsequently received 2nd line chemotherapy and FP-based regimens were used in 321 pts (97%). Results: The median age was 60 years (range, 27-82) and 57% of pts were male. Intrahepatic cholangiocarcinoma(IH-CCC) (44%) was the most common type, and followed by extrahepatic cholangiocarcinoma (32%). Most pts (n = 289, 89%) had metastatic/recurrent disease at the time of 1st line treatment. FP alone and FP plus platinum combination were used in 255 pts (79%) and 66 pts (21%), respectively. In pts with measurable disease, response rate (RR) was 3% (8/301) and disease control rate was 47% (142/301). After a median follow-up of 27.6 months (0.9-70.4 months), the median progression free survival (PFS) and overall survival (OS) were 1.9 months (95% CI, 1.6-2.2) and 6.5 months (95% CI, 5.9-7.0). RR was significantly higher in pts with combination of FP and platinum compared to FP alone (8% vs 1%, p = 0.009). However, there were no statistically significant differences in terms of PFS (p = 0.43) or OS (p = 0.88) between two groups. In the multivariate analysis for OS, IH-CCC, initially metastatic disease and elevated CA 19-9 level at the time of 1st line treatment, and time-to-progression at 1st line GEMCIS > 4 months were independent poor prognostic factors. Conclusions: In this analysis, FP-based regimen showed modest efficacy as 2nd line chemotherapy for advanced BTC patients after failure of 1st line GEMCIS. Combination of FP and platinum was not associated with improved survival outcomes compared to FP monotherapy, despite of higher RR.
12
Pasquin, Matteo, Po-Yin Cheung, Michael Wagner, Tze-Fun Lee, Megan O’Reilly, and Georg Schmolzer. "USING DIFFERENT CHEST COMPRESSIONS AND VENTILATION RATIOS (2:1, 3:1, 4:1) DURING NEONATAL ASPHYXIA IN A PORCINE MODEL OF NEONATAL RESUSCITATION – A RANDOMIZED CONTROLLED ANIMAL TRIAL." Paediatrics & Child Health 23, suppl_1 (May 18, 2018): e21-e22. http://dx.doi.org/10.1093/pch/pxy054.054.
Abstract:
Abstract BACKGROUND The rationale for a compression to ventilation ratio of 3:1 in neonates with primary hypoxic, hypercapnic cardiac arrest is to emphasize the importance of ventilation; however, there are no published studies testing this approach against alternative methods. OBJECTIVES To evaluate if using a 2:1 C:V ratio or a 4:1 C:V ratio will improve ROSC compared to using a 3:1 C:V ratio. DESIGN/METHODS Term newborn piglets were anesthetized, intubated, instrumented, and exposed to 40-min normocapnic hypoxia followed by asphyxia. Asphyxia was achieved by clamping the endotracheal tube until the piglet had asystole; at that time CPR was initiated. Piglets were then randomized into 3 groups: 2:1 C:V ratio (n=8), 3:1 ratio (n=8), 4:1 C:V ratio (n=8), or a sham operated group. A two-step randomization was used to reduce selection bias. After surgical instrumentation and stabilization, a sequentially numbered, sealed brown envelope containing the allocation “sham” or “intervention” was opened (step one). The sham-operated group had the same surgical protocol, stabilization, and equivalent experimental periods without hypoxia and asphyxia. Only piglets randomized to “intervention” underwent hypoxia and asphyxia. Once the criteria for CPR were met, a second envelope containing the allocations “2:1”,“3:1”,or “4:1”, was opened (step two). Cardiac function, carotid blood flow, cerebral oxygenation, and respiratory parameters were continuously recorded throughout the experiment. RESULTS The median (IQR) duration of asphyxia was similar between the groups with 318 (194–576)sec, 255 (226–334)sec, 233 (169–395)sec for 2:1, 3:1, 4:1 C:V, respectively (p=0.68; oneway ANOVA with Bonferroni). The median (IQR) time to ROSC was also similar between groups 127 (82–210)sec, 96 (88–126)sec, 119 (83–256)sec for 2:1, 3:1, 4:1 C:V, respectively (p=0.67; oneway ANOVA with Bonferroni). Overall, 8/8 in the 2:1 C:V ratio group, 7/8 in the 3:1 C:V ratio group, and 7/8 in the 4:1 C:V ratio group survived. CONCLUSION There was no significant difference in time to ROSC for either chest compression technique during cardiopulmonary resuscitation in a porcine model of neonatal asphyxia.
13
Hsieh, Matthew M., Beth Link, Roberto Machado, Gregory Kato, Mark Gladwin, and John F. Tisdale. "Improvement in Hemolytic Parameters and Tricuspid Regurgitant Jet Velocity (TRV) Following Non-Myeloablative Allogeneic Stem Cell Transplantation (allo-SCT) in Adults with Severe Sickle Cell Disease (SCD)." Blood 110, no. 11 (November 16, 2007): 843. http://dx.doi.org/10.1182/blood.v110.11.843.843.
Abstract:
Abstract Although SCD has a variable clinical course, many individuals develop end-organ complications that are associated with significant morbidity and early mortality. SCD-related pulmonary hypertension is a frequently recognized complication (up to 30%), is associated with significant mortality, and is resistant to hydroxyurea or chronic exchange transfusions. Currently myeloablative allo-SCT in children under age 16 is curative in the majority, preventing or ameliorating many of the complications of the disease. However, it is unclear whether reduced intensity allo-SCT in adults that allows mixed hematopoietic chimerism could offer the same benefit. Furthermore, reversal of pulmonary hypertension has not been previously demonstrated in either setting. Beginning in 2003, we initiated an IRB approved clinical trial testing a nonmyeloablative approach in adults with severe SCD. Protocol entry criteria include end-organ complications, (stroke, pulmonary hypertension TRV≥ 2.5 m/s, or frequent vaso-occlusive crises or acute chest syndrome not ameliorated by hydroxyurea. Conditioning was achieved with low dose radiation, alemtuzumab, and sirolimus (rapamycin). All patients receive unmanipulated G-CSF mobilized peripheral blood progenitors obtained from an HLA-matched sibling. Assessment of donor chimerism is measured by microsatellite PCR of CD3 and CD14/15 positive white cells. Hemolysis is monitored by serial measurements of total bilirubin, lactate dehydrogenase, hemoglobin and absolute reticulocyte counts. Transthoracic echocardiography is performed in all patients, and serially in those with TRV ≥ 2.5 m/s. Transmitral flow, Doppler determinations of valvular regurgitant velocity, and left ventricular stroke volume are assessed and graded. A total of 8 patients have accrued. 4 of 8 patients met criteria for pulmonary hypertension. Post transplant follow-up for these 4 patients ranged from 7 to 36 months and stable donor lymphoid (13–39%) and myeloid (53–100%) chimerism was observed in all 4. This pattern of mixed chimerism was sufficient for full donor erythroid engraftment as all demonstrated normal hemoglobin, allowing for therapeutic phlebotomy to correct transfusional iron overload. Improvement in TRV and hemolytic parameters were observed (see table) as early as 3 months post transplant. The average pre- and post allo-SCT values were: TRV 3.1 → 2.5 m/s (p=0.13, Wilcoxon rank sum), total bilirubin 4.0 → 0.6 (p=0.1), lactate dehydrogenase 487 →178 units/L (p=0.2), hemoglobin (hgb) 8.6 → 12.6 g/dL (p=0.002), and reticulocyte (retic) count 326 → 68 k/uL (p=0.01). Our results indicate that reduced intensity allo-SCT in adults patients with SCD allows for full donor erythroid engraftment, normalization of blood counts, reversal of hemolysis, and improvement in TRV. TRV and hemolytic parameters Patient 1 Patient 2 Patient 3 Patient 4 Average TRV Pre 3.7 2.6 3.4 2.6 3.08 (m/s) BMT 2.6 2.4 2.5 2.3 2.45 T bili Pre 8.3 4.0 1.9 1.9 4.0 (0.1–1.1 mg/dL) BMT 0.8 0.5 0.5 0.4 0.6 LDH Pre 1065 330 338 215 487 113–226 units/L) BMT 234 178 209 90 178 Hgb Pre 8.1 8.5 8.8 8.9 8.6 (g/dL) BMT 12.9 13.9 11.9 11.6 12.6 Retic Pre 344 213 417 331 326 (31–105 k/uL) BMT 76 32 76 87 68
14
Adler, K. H. "Vichy Specificities: Repositioning the French Past." Contemporary European History 9, no. 3 (November 2000): 475–88. http://dx.doi.org/10.1017/s0960777300003106.
Abstract:
Michèle and Jean-Paul Cointet, eds., Dictionnaire historique de la France sous l'Occupation (Paris: Tallandier, 2000), 732pp., FF 290, ISBN 2-235-02234-0. Hanna Diamond, Women and the Second World War in France 1939–1948: Choices and Constraints (Harlow: Longman, 1999), 231pp., £45.00 (hb), £14.99 (pb), ISBN 0-582-29909-8. Sarah Fishman, Laura Lee Downs, Ioannis Sinanoglou, Leonard V. Smith, Robert Zaretsky, eds., France at War: Vichy and the Historians (Oxford and New York: Berg, 2000), 336pp., £45.00, ISBN 1-859-73299-2. Bertram M. Gordon, ed., Historical Dictionary of World War II France: The Occupation, Vichy, and the Resistance, 1938–1946 (Westport: Greenwood Press, 1998), 433pp., £73.95, ISBN 0-313-29421-6. Miranda Pollard, Reign of Virtue: Mobilizing Gender in Vichy France (Chicago and London: University of Chicago Press, 1998), 285pp., £31.50 (hb), £14.00 (pb), ISBN 0-226-67349-9 and 0-226-67350-2. Lynne Taylor, Between Resistance and Collaboration: Popular Protest in Northern France, 1940–45 (Basingstoke: Macmillan; New York: St. Martin's Press, 2000), 195pp., £40.00, ISBN 0-333-73640-0.
15
Baes, Jonas. "Mathias Spahlinger. By Neil Thomas Smith. Bristol: Intellect Books 2021. 206 pp. ISBN 978 78938 334 8." Popular Music 41, no. 2 (May 2022): 266–68. http://dx.doi.org/10.1017/s0261143022000290.
16
Libeiro, Sirus. "L. G. Searle, Landscapes of Accumulation: Real Estate and the Neoliberal Imagination in Contemporary India." Urbanisation 2, no. 1 (May 2017): 78–80. http://dx.doi.org/10.1177/2455747117696636.
17
Galán, Montaña Caballero. "La conservación preventiva de los Bienes Culturales." Ge-conservacion 6 (December 14, 2014): 104–5. http://dx.doi.org/10.37558/gec.v6i0.251.
Abstract:
Reseña del libro: La conservación preventiva de los bienes culturales Autora: Isabel García Fernández Alianza Forma, Madrid, 2013. 301 páginas, ilustraciones en blanco y negro, 18x23 cm. ISBN: 978-84-206-7856-8
18
Kyriakis, S. C., V. Vassilopoulos, I. Demade, W. Kissels, Z. Polizopoulou, and C. K. Milner. "The effect of virginiamycin on sow and litter performance." Animal Science 55, no. 3 (December 1992): 431–36. http://dx.doi.org/10.1017/s0003356100021139.
Abstract:
AbstractThe present paper discusses the results of a trial study, which was carried out to demonstrate the potential beneficial effects of virginiamycin (VM) on sow and litter performance. VM was added to the sow food at the levels of 0, 20 and 40 mg/kg, for a period of two breeding cycles, covering pregnancy and lactation. VM supplementation of the sow food improved sow performance by: (i) decreasing sow weight loss from farrowing to weaning (first period: 8·78 v. 3·54 v. 2·88 kg, P < 0·05; second period: 8·98 v. 3·93 v. 2·32 kg, P < 0·05), (ii) decreasing the duration of the reproductive cycle (first period: 154·5 v. 152·2 v. 151·2 days, P < 0·05; second period: 153·8 v. 151·5 v. 250·6 days, P < 0·05) and (in) increasing milk fat content (second period: 63·7 v. 81·3 v. 83·3 g/kg, P<0·05). Litter performance was also improved in terms of: (i) litter size at weaning (first period: 8·16 v. 8·88 v. 9·18, P < 0·05; second period: 8·98 v. 9·30 v. 9·76, P < 0·05), (ii) body weight at weaning (first period: 5·78 v. 6·29 v. 6·56 kg, P < 0·05; second period: 5·88 v. 6·38 v. 6·60 kg, P < 0·05), (Hi) average daily gain (first period: 172 v. 189 v. 197 g, P < 0·05; second period: 178 v. 292 v. 198 g, P < 0·05) and (iv) food conversion ratio (first period: 0·356 v. 0·331 v. 0·324, P < 0·05; second period: 0·363 v. 0·334 v. 0·325, P < 0·05). These beneficial effects of VM were more pronounced at the higher of the two inclusion levels.
19
Porath, Kendra A., Ann Mladek, Rachael A. Vaubel, Michael S. Regan, Sonia Jain, Danielle Burgenske, Katrina Bakken, et al. "Abstract 334: Convection enhanced delivery of EGFR-targeting antibody drug conjugates ABBV-321 and Depatux-M." Cancer Research 82, no. 12_Supplement (June 15, 2022): 334. http://dx.doi.org/10.1158/1538-7445.am2022-334.
Abstract:
Abstract Introduction: EGFR targeted antibody-drug conjugates (ADCs) show promise as a novel treatment in a subset of glioblastoma (GBM). Two EGFR targeting ADCs include first generation Depatux-M, with an antimitotic toxin monomethyl auristatin F (MMAF), and ABBV-321, with a DNA crosslinking agent pyrrolobenzodiazepine dimer (PBD) toxin. Due to the large molecular weight, poor drug distribution across the blood-brain barrier significantly limits the efficacy in EGFR-amplified GBM. We studied whether convection enhanced delivery (CED) can be used to safely infuse these two EGFR-targeted ADCs in patient-derived xenograft (PDX) models of EGFR-amplified GBM. Methods: The efficacy of Depatux-M and ABBV-321 was evaluated in vitro and in vivo in two EGFRviii-amplified PDXs (GBM6 and GBM108). Immunofluorescence staining was used to evaluate drug distribution along with pharmacodynamics of the ADCs. CED was performed by stereotactic placement of an infusion catheter in the same location as the original tumor implantation. Immunohistochemistry was used to explore mechanisms of normal cell toxicity. Results: Despite potent activity in vitro (high ng/ml IC50), systemic administration of either ADC conferred minimal extension in survival for either GBM6 or GBM108. In contrast, CED significantly enhanced ADC delivery to tumor and peri-tumoral regions and extended survival. In a pilot study in GBM6 with n=3 mice per group, a single CED infusion of 0.002mg ABBV-321 resulted in extended survival beyond 365 days for two mice, while other doses and placebo were associated with shorter median survival (0 mg - 39 days; 0.03 mg - 105 days; 0.3 mg - 49 days). In a subsequent trial evaluating serial infusions performed every 21 days, four infusions at 0.002 mg ABBV-321 resulted in lethal toxicity. In contrast, limiting ABBV-321 to only two serial CED infusions in GBM108 was associated with extended survival of more than 300 days vs. 53 days for AB095 antibody control infusion. In contrast, serial infusion with Depatux-M was much better tolerated. In a single infusion in GBM6, a 0.06 mg dose was well tolerated and associated with a 49-day extension in median survival. Further, four serial infusions at 0.06 mg given every 21 days in GBM6 and GBM108 was associated with 100 day and more than 250-day extension in survival as compared to AB095 antibody control infusion. To investigate the mechanism of toxicity, infusion of non-tumor bearing C57Bl6 mice with ABBV-321 resulted in a marked loss in NeuN staining and elevated CD68 and GFAP staining 7 days later; Depatux-M infusion was only associated with modest elevation in GFAP without loss of NeuN staining or elevated CD68-positive cells. Conclusion: Depatux-M is well tolerated when infused into normal brain and results in extended survival in orthotopic GBM PDXs. In contrast, ABBV-321, with a distinct PBD toxin, had a much narrower therapeutic window when delivered by CED. Citation Format: Kendra A. Porath, Ann Mladek, Rachael A. Vaubel, Michael S. Regan, Sonia Jain, Danielle Burgenske, Katrina Bakken, Brett Carlson, Margaret Connors, Zeng Hu, Lihong He, Paul A. Decker, Gaspar Kitange, Shiv Gupta, Nathalie Y. Agar, Thomas M. Feldsien, Didier R. Lefebvre, Jann N. Sarkaria. Convection enhanced delivery of EGFR-targeting antibody drug conjugates ABBV-321 and Depatux-M [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 334.
20
Wholey, Michael Henry, Mark Henry Wholey, Gustave Eles, Boulis Toursakissian, Steven Bailey, Chester Jarmolowski, and Walter A. Tan. "Evaluation of Glycoprotein IIb/IIIa Inhibitors in Carotid Angioplasty and Stenting." Journal of Endovascular Therapy 10, no. 1 (February 2003): 33–41. http://dx.doi.org/10.1177/152660280301000108.
Abstract:
Purpose: To review the immediate neurological and bleeding complications associated with the use of glycoprotein (GP) IIb/IIIa inhibitors in patients undergoing extracranial carotid artery stent placement. Methods: A retrospective review was performed of 550 patients (321 men; mean age 71.1 years, range 28–91) who underwent carotid artery angioplasty and stent placement. Glycoprotein IIb/IIIa inhibitors were given prophylactically along with heparin to 216 patients, whose outcomes were compared to a control group of 334 patients who received intravenous heparin alone. Primary endpoints were the immediate and 30-day neurological complications, including transient ischemic attacks (TIAs), minor and major strokes, and neurologically-related deaths. The secondary endpoint was any abnormal bleeding. Results: The all stroke/neurological death rate in 216 patients treated with heparin and GP IIb/IIIa inhibitors was 6.0% (13 events) compared 2.4% (8 events) in the 334 patients in the heparin-only control group (p = 0.0430). Two of the 4 neurologically-related deaths in the GP IIb/IIIa inhibitor group resulted from intracranial hemorrhages; there were no intracranial hemorrhages in the heparin-only group. There was 1 episode of extracranial bleeding in the GP IIb/IIIa inhibitor group treated with embolization. The incidences of significant puncture-site bleeding requiring transfusion were similar in the groups. Conclusions: Neurological complications following percutaneous carotid artery interventions have been relatively few. The neurological sequelae in carotid stent patients receiving glycoprotein IIb/IIIa inhibitors were more numerous and consequential, which suggests that the use of GP IIb/IIIa inhibitors in carotid stenting should be discouraged.
21
Strand, V., S. Bender, and D. Mccabe. "AB0437 IMMUNOGENICITY ANALYSIS FROM THE VOLTAIRE TRIALS IN PATIENTS WITH RHEUMATOID ARTHRITIS, CROHN’S DISEASE, AND CHRONIC PLAQUE PSORIASIS." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 1407.2–1407. http://dx.doi.org/10.1136/annrheumdis-2023-eular.443.
Abstract:
BackgroundThe VOLTAIRE trials program compared safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severely active rheumatoid arthritis (RA), Crohn’s disease (CD), and chronic plaque psoriasis (PsO). Details of each active-comparator, randomized controlled trial (RCT) are published.[1,2,3]ObjectivesHere we compare immunogenicity across these indications and by patient sex.MethodsImmunogenicity was assessed at various timepoints by the proportion of patients with anti-drug antibodies (ADAs) and neutralising antibodies (nAbs), using acid dissociation followed by an electrochemiluminescence assay (ECL; MSD platform; Meso Scale Diagnostics LLC, USA).[4]Assay sensitivity was 50 ng/mL, and drug tolerance ≥30 μg/mL (free drug) at the low positive control level.ResultsData are presented inTable 1.Table 1.Immunogenicity dataVOLTAIRE-RAVOLTAIRE-CDVOLTAIRE-PsOBI 695501RPBI 695501RPBI 695501RPAntibody first detectableADABaselineBaselineBaselineWeek 4aBaselineBaselinenAbBaselineBaselineWeek 4aWeek 4aBaselineBaselineADA titre at primary endpoint, mean (SD)54.1 (93.54)at wk 12163.2 (753.96)at wk 24353.5 (1816.96) at wk 12294.7 (1555.05) at wk 24647.9 (2176.14) at wk 417.5 (31.03) at wk 432.0 (1, 16384) at wk 16b32.0 (1, 8192) at wk 16bProportion of patients with antibodies (ADAs and nAbs) over timeADA positiveccBaseline3.4% (11/323)6.5% (21/321)4.3% (3/69)0% (0/74)10.7% (17/159)10.8% (17/158)Day 7 (Wk 1)5.7% (18/317)9.3% (29/311)Day 14 (Wk 2)10.1% (32/318)16.0% (51/318)Day 28 (Wk 4)20.1% (64/319)19.7% (62/315)20.6% (14/68)b5.5% (4/73)bDay 84 (Wk 12)32.4% (101/312)34.9% (106/304)Day 113 (Wk 16)68.2% (101/148)71.8% (107/149)Day 168 (Wk 24)43.2% (127/294)47.8% (144/301)nAb positiveccBaseline2.8% (9/323)5.0% (16/321)0% (0/69)0% (0/74)0.6% (1/159)1.9% (3/158)Day 7 (Wk 1)2.5% (8/317)3.9% (12/311)Day 14 (Wk 2)3.1% (10/318)8.2% (26/318)Day 28 (Wk 4)6.9% (22/319)7.3% (23/315)8.8% (6/68)a2.7% (2/73)aDay 84 (Wk 12)13.1% (41/312)16.8% (51/304)Day 113 (Wk 16)54.1% (80/148)55.7% (83/149)Day 168 (Wk 24)16.0% (47/294)20.6% (62/301)Proportion of patients with ADA antibodies by subgroupSexWk 12Male (13/53)24.5%Female (88/259)34.0%Wk 24Male (19/50)38.0%Female (110/246)44.7%Wk 12Male (18/47)38.3%Female (88/257)34.2%Wk 24Male (25/47)53.2%Female (119/254)46.9%Wk 4Male (8/37)21.6%Female (6/31)19.4%Wk 4Male (2/42)4.8%Female (2/31)6.5%Wk 16Male (65/93)69.9%Female (36/55)65.5%Wk 16Male (66/97)68.0%Female (41/52)78.8%a. Wk 4 = Day 29 in CD trial; b. Median (minimum, maximum); c. Reported by randomisation completed at baselineConclusionMinor differences in immunogenicity (ADAs, ADA titres and nAbs) between BI 695501 and adalimumab RP were observed across these 3 indications. The proportion of ADA- and nAb-positive patients increased from baseline in all 3 RCTs, and were similar in RA and CD RCTs, but rates were higher in PsO RCT. Subgroup analysis by patient sex showed the same trend. These differences may be partially explained by concomitant background therapy (MTX) in RA trial, stable doses of AZA, 6-MP or MTX in 36% of CD patients and the absence of background therapy in PsO RCT. Comparisons are limited by different visit schedules in the trials. Historical comparisons to RP data are complicated by recent differences in regulatory requirements for increased ADA assay sensitivity and stringency for biosimilar products than those originally used for the RP. Acid dissociation followed by the more sensitive ECL assay for detection of ADAs is not dependent on serum drug concentrations. In conclusion, these analyses confirm the biosimilarity of BI 695501 with the adalimumab RP across RA, CD, and PsO.References[1] Cohen SB, et al. Ann Rheum Dis. 2018;77:91-21.[2] Hanauer S, et al. Lancet Gastroenterol Hepatol. 2021;6:816-25.[3] Menter A, et al. Expert Opin Biol Ther. 2021;21:87-96.[4] Wynne C, et al. Expert Opin Inv Drugs 2016;25:1361-70.AcknowledgementsThe authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors. The authors received no direct compensation related to the development of the abstract. Writing support was provided by Debra Brocksmith, MB ChB, PhD, of Elevate Scientific Solutions (Envision Pharma Group), which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI was given the opportunity to review the abstract for medical and scientific accuracy.Disclosure of InterestsVibeke Strand Consultant of: AbbVie, Amgen, Aria, AstraZeneca, Bayer, Bioventus, Blackrock, BMS, Boehringer Ingelheim, Celltrion, Chemocentryx, Equillium, Gilead, Genentech/Roche, Glenmark, GSK, Horizon, Inmedix, Janssen, Kiniksa, Kypha, Lilly, Merck, MiMedx, Novartis, Pfizer, Priovant, Regeneron, Rheos, R-Pharma, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Sorrento, Spherix, and Tonix, Shaun Bender Employee of: Boehringer Ingelheim Pharmaceuticals, Inc. (previous employment), Dorothy McCabe Employee of: Boehringer Ingelheim Pharmaceuticals, Inc.
22
Schaefer, Ted, and Glenn H. Penner. "Mechanisms of 1H,1H; 1H,13C; and 13C,13C spin–spin coupling constants in benzyl cyanide and some derivatives. Experimental and theoretical estimates of internal rotational potentials." Canadian Journal of Chemistry 64, no. 10 (October 1, 1986): 2013–20. http://dx.doi.org/10.1139/v86-333.
Abstract:
The mechanisms of long-range spin–spin coupling constants involving the methylene protons and the 13C nucleus of the cyano group are discussed for benzyl cyanide. Analysis of the 1H nmr spectrum of benzyl cyanide-8-13C in benzene-d6 solution yields nJ(H,CH2) and nJ(H,13CN) for n = 4–6. Similar data are reported for the 2,6-dichloro and 2,6-difluoro derivatives, together with some sign determinations. nJ(13C,13CN), n = 1–5, are given for the three compounds. It is shown that all these parameters are consistent with a small barrier to internal rotation about the [Formula: see text] bond in benzyl cyanide in solution. Computations at various levels of molecular orbital theory agree that this barrier is small. The nJ(13C, 13CN) imply a stabilization in polar solvents of the conformation in which the cyano group of benzyl cyanide lies in a plane perpendicular to the benzene plane. The molecular orbital calculations indicate a predominantly twofold nature of the internal barrier, although a significant fourfold component is also present. The coupling constants cannot discern the presence of the fourfold component for benzyl cyanide nor for its 2,6-difluoro derivative. 1J(13C,13CN) is solvent dependent. A table of the computed sidechain geometries is appended.
23
Kuzmik, Ashley, Barbara Resnick, Pamela Cacchione, Rachel Arendacs, and Marie Boltz. "Physical Activity in Hospitalized Persons With Dementia: Feasibility and Validity of the MotionWatch 8." Journal of Aging and Physical Activity 29, no. 5 (October 1, 2021): 852–57. http://dx.doi.org/10.1123/japa.2020-0275.
Abstract:
Persons with dementia are at high risk for hospital-acquired disability, associated with low physical activity during hospitalizations. To determine the effectiveness of efforts to increase physical activity, a valid and reliable measurement approach is required. Data from an ongoing cluster randomized clinical trial examined the feasibility and validity of the MotionWatch 8 (MW8) triaxial actigraphy device. The sample included 321 participants of which 259 (81%) were willing to wear the MW8 for 24 hr. Regression analysis revealed that time in low activity, β = 0.17, t(255) = 2.9, p = .004, and time in moderate activity, β = 0.14, t(255) = 2.4, p = .017, measured by the MW8, were associated with participants’ physical function. Engagement in moderate physical activity was associated with return to baseline function at discharge (Wald χ2 = 4.10, df = 1, p = .043). The study provides preliminary support for the feasibility and validity of the MW8 in hospitalized persons with dementia.
24
Weber, Simone, Tamara Alpermann, Christiane Eder, Frank Dicker, Sabine Jeromin, Alexander Kohlmann, Annette Fasan, et al. "High BAALC Expression in Cytogenetically Normal Acute Myeloid Leukemia Strongly Correlates with Adverse Markers Such As RUNX1mut, MLL-PTD and FLT3-ITD and Is Useful for Disease Monitoring." Blood 120, no. 21 (November 16, 2012): 1376. http://dx.doi.org/10.1182/blood.v120.21.1376.1376.
Abstract:
Abstract Abstract 1376 Introduction: BAALC expression is thoroughly explored in cytogenetically normal AML (CN-AML) and has been shown to be associated with an adverse outcome. Nevertheless, its prognostic importance in relation to other molecular markers and its relevance for detection of minimal residual disease (MRD) remains to be defined. The objective of this study was to evaluate the prognostic impact of BAALC expression on clinical outcome in the context of other relevant molecular prognosticators and to examine its utility as a marker for detection of MRD in CN-AML. Patients: BAALC mRNA expression was analyzed in a cohort of 332 patients with de novo CN-AML. The cohort was composed of 169 females (50.9%) and 163 males (49.1%). Age ranged from 18.3 to 64.8 years (median: 52.9). Data on other molecular markers was available in: FLT3-ITD: n=332, NPM1: n=332, RUNX1: n=330, CEBPA: n=332, MLL-PTD: n=332, ASXL1: n=330, FLT3-TKD: n=331, IDH1G105: n=229, IDH1R132: n=253, IDH2: n=232, NRAS: n=254, WT1 mut: n=247, TET2: n=74 and TP53: n=182. In addition, BAALC expression was assessed in 25 follow-up samples of 8 patients in comparison with an established MRD marker. Methods: To assess BAALC mRNA expression levels RQ-PCR was performed by the use of the Applied Biosystems 7500 Fast Real Time PCR System. BAALC expression was normalized against the expression of the control gene ABL1. The median ratio BAALC/ABL1 was used to separate low from high BAALC expressers. Expression data of diagnostic samples was correlated to clinical outcomes and to the presence of molecular mutations. BAALC expression ratios of follow-up samples were also correlated to the status of other molecular markers available in the same patients. Results: 1) Evaluation of prognostic relevance: Expression ratios of BAALC/ABL1 represented a continuum ranging from 0.001 to 80.199 (median: 0.321). In agreement with previous studies, patients with high BAALC expression had shorter overall survival (OS at 3 years: 51.4% vs 73.0%, p=0.046) and event free survival (EFS at 3 years: 38.5% vs 50.6%, p=0.021) as compared to low BAALC expressers. Though, associations of BAALC expression to other molecular markers were found. In high BAALC expressers, as compared to low BAALC expressers, the following mutations were more frequent: RUNX1 mut (32/164, 19.5% vs 2/166, 1.2%, p<0.001), MLL-PTD (22/166, 13.3% vs 5/166, 3.0%, p=0.001) and FLT3-ITDmut/wt ratio>0.5 (51/166, 30.7% vs 24/166, 14.5%, p=0.001), whereas NPM1 mut were less frequent (72/166, 43.3% vs 138/166, 83.1%, p<0.001). In univariable Cox regression analyses shorter OS and EFS was associated with higher age, higher WBC count, high BAALC expression and the presence of at least one of the established adverse markers RUNX1 mut, MLL-PTD, or FLT3-ITDmut/wt ratio>0.5 grouped together as one parameter (OS, p<0.001, <0.001, 0.0048, <0.001, respectively; EFS, p=0.002, <0.001, 0.022, <0.001, respectively). In multivariable models, BAALC expression had an independent impact on EFS (p=0.042) but not on OS. Further, Kaplan Meier analysis within the subgroup with adverse markers (RUNX1 mut, MLL-PTD, or FLT3-ITDmut/wt ratio>0.5, n=98) revealed no additional impact of BAALC expression on OS or EFS. Also within the prognostically favorable subgroup with NPM1 mut/FLT3-ITDmut/wt ratio<0.5 high BAALC expression had no impact on OS or EFS. 2) Validation as follow-up marker: To evaluate the impact of BAALC expression for disease monitoring during follow-up, the BAALC/ABL1 ratio of high BAALC expressers was compared to the %MLL-PTD/ABL1 or %RUNX1 mut levels in patients who had at least one of these aberrations in parallel. In total, 33 diagnostic and follow-up samples of 8 patients were analyzed. Comparison of BAALC/ABL1 ratios to mutational status of MLL-PTD and/or RUNX1 revealed a significant correlation (r=0.577, p<0.001). Additionally, in one case with paired samples at diagnosis and relapse, BAALC expression levels at diagnosis and at relapse were in the same range (BAALC/ABL1: 10.870 vs 17.600). Conclusion: 1) BAALC expression in CN-AML predicts an adverse clinical outcome, but is associated with other well established prognostic markers. Thus, in our study BAALC expression had no independent prognostic impact on OS when analyzed together with RUNX1, MLL-PTD, FLT3-ITD and NPM1. 2) Correlation of BAALC expression with MLL-PTD and RUNX1 during follow up indicates that BAALC expression is a potential target for MRD monitoring. Disclosures: Weber: MLL Munich Leukemia Laboratory: Employment. Alpermann:MLL Munich Leukemia Laboratory: Employment. Eder:MLL Munich Leukemia Laboratory: Employment. Dicker:MLL Munich Leukemia Laboratory: Employment. Jeromin:MLL Munich Leukemia Laboratory: Employment. Kohlmann:MLL Munich Leukemia Laboratory: Employment. Fasan:MLL Munich Leukemia Laboratory: Employment. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership. Kern:MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership. Schnittger:MLL Munich Leukemia Laboratory: Equity Ownership.
25
Peterson, Ivan V., Nadezhda M. Svirskaya, Alexander A. Kondrasenko, and Anatoliy I. Rubaylo. "1-Adamantanol Alkylation of 1,2-; 2,6- and 2,7-Dihydroxynaphthalens." Journal of Siberian Federal University. Chemistry 8, no. 2 (June 2015): 301–5. http://dx.doi.org/10.17516/1998-2836-2015-8-2-301-305.
26
Wichert, Sabine. "The Northern Ireland Conflict: New Wine in Old Bottles?" Contemporary European History 9, no. 2 (July 2000): 307–22. http://dx.doi.org/10.1017/s0960777300002095.
Abstract:
James Loughlin, The Ulster Question since 1945 (London: Macmillan, 1998), 151 pp., £10.99 (pb), ISBN 0–333–60616–7.David Harkness, Ireland in the Twentieth Century. Divided Island (London: Macmillan, 1996), 190 pp., £9.99 (pb), ISBN 0–333–56796–X.Thomas Hennessey, A History of Northern Ireland, 1920–1996 (London: Macmillan, 1997), 347 pp., £12.99 (pb), £40.00 (hb), ISBN 0–333–73162–X.Brian A. Follis, A State Under Siege. The Establishment of Northern Ireland, 1920–1925 (Oxford: Clarendon, 1995), 250 pp., £35.00 (hb), ISBN 0–198–20305–5.Dermot Keogh and Michael H. Haltzel, eds., Northern Ireland and the Politics of reconciliation (Cambridge: Cambridge University Press, 1994), 256 pp., £35.00 (hb), ISBN 0–521–44430–6.William Crotty and David Schmitt, eds., Ireland and the Politics of Change (London/New York: Longman, 1999), 264 pp., £17.99 (pb), ISBN 0–582–32894–2.David Miller, ed., Rethinking Northern Ireland. Culture, Ideology and Colonialism. (London/New York: Longman, 1999), 344 pp., £17.99 (pb), ISBN 0–582–30287–0.Anthony D. Buckley and Mary Catherine Kenney, Negotiating Identity: Rhetoric, Metaphor, and Social Identity in Northern Ireland (Washington: Smithonian Institution Press, 1996), 270 pp., £34.75 (hb), ISBN 1–560–98520–8.John D. Brewer, with Gareth I. Higgins, Anti-Catholicism in Northern Ireland, 1600–1998: the mote and the beam (London: Macmillan, 1998), 248 pp., £16.99 (pb), ISBN 0–333–74635–X.During the last three decades, and accompanying the ‘troubles’, the literature on Northern Ireland has mushroomed. Within the last ten years two surveys have attempted to summarise and categorise the major interpretations. John Whyte's Interpreting Northern Ireland covered the 1970s and 1980s and came to the conclusion that traditional Unionist and nationalist interpretations, with their emphasis on external, that is British and Irish, forces as the cause for the problem, had begun to lose out to ‘internal conflict’ interpretations. He felt, however, that this approach, too, was coming to the end of its usefulness, and he expected the emergence of a new paradigm shortly.
27
Schellenberg, Inga, Tom Nilges, and Rainer Pöttgen. "Structural and 121Sb Mössbauer Spectroscopic Investigations of the Antimonide Oxides REMnSbO (RE = La, Ce, Pr, Nd, Sm, Gd, Tb) and REZnSbO (RE = La, Ce, Pr)." Zeitschrift für Naturforschung B 63, no. 7 (July 1, 2008): 834–40. http://dx.doi.org/10.1515/znb-2008-0705.
Abstract:
Quaternary antimonide oxides REMnSbO (RE = La, Ce, Pr, Nd, Sm,Gd, Tb) and REZnSbO (RE = La, Ce, Pr) were synthesized from the RESb monoantimonides and MnO, respectively ZnO, in sealed tubes at 1170 K. Single crystals were obtained from NaCl/KCl salt fluxes. The ZrCuSiAs-type (space group P4/nmm) structures of LaMnSbO (a = 423.95(7), c = 955.5(27) pm, wR2 = 0.067, 247 F2), CeMnSbO (a = 420.8(1), c = 950.7(1) pm, wR2 = 0.097, 250 F2), SmMnSbO (a = 413.1(1), c = 942.3(1) pm, wR2 = 0.068, 330 F2), LaZnSbO (a = 422.67(6), c = 953.8(2) pm, wR2 = 0.052, 259 F2), and NdZnSbO (a = 415.9(1), c = 945.4(4) pm, wR2 = 0.109, 206 F2) were refined from single crystal X-ray diffractometer data. The structures consist of covalently bonded (RE3+O2−)+ and (T2+Sb3−)− layers with weak ionic interlayer interactions. The oxygen and transition metal atoms both have tetrahedral coordination within the layers. 121Sb Mössbauer spectra of the REMnSbO and REZnSbO compounds show single antimony sites with isomer shifts close to −8 mm s−1, in agreement with the antimonide character of these compounds. PrMnSbO and NdMnSbO show transferred hyperfine fields of 8 T at 4.2 K.
28
Mariappanadar, Sugumar, and Wayne A. Hochwarter. "A Three-Way Synergistic Effect of Work on Employee Well-Being: Human Sustainability Perspective." International Journal of Environmental Research and Public Health 19, no. 22 (November 11, 2022): 14842. http://dx.doi.org/10.3390/ijerph192214842.
Abstract:
We explored the interaction of the United Nation’s sustainable development goals to facilitate human sustainability using occupational health and sustainable HRM perspectives. In Study 1 (n = 246), we assessed the preconditions to empirically confirm the distinctiveness of the dimensions of health harm of work from other study constructs. Subsequently, we tested the hypotheses across two studies (n = 332, Study 2; n = 255, Study 3). In alignment with the ceiling effect of human energy theory, the three-way interaction results across the samples consistently indicate that high supervisory political support (SPS) significantly strengthens the negative interactions of psychological health risk factors and high job tension as adverse working conditions (SDG-8) on working-condition-related well-being as the human sustainability dimension (SDG-3). Similarly, synergistic effects were found of the side effects of work on health, high job tension, and high SPS on well-being in sample 3. We discuss theoretical and future research for human sustainability from occupational health and sustainable HRM perspectives.
29
Park, Junghyun, and Marc Rodger. "Retrospective Cohort of Unprovoked Venous Thromboembolism Patients: What Proportion Have Potent Thrombophilias Necessitating Indefinite Anticoagulants?" Blood 126, no. 23 (December 3, 2015): 2318. http://dx.doi.org/10.1182/blood.v126.23.2318.2318.
Abstract:
Introduction Thrombophilia testing in unprovoked venous thromboembolism patients (VTE) is controversial. Common thrombophilias such as Factor V Leiden or prothrombin gene variant appear to not importantly increase the risk of VTE recurrence, and thus are not considered in anticoagulation management decisions. However, patients with potent thrombophilias such as antiphospholipid antibodies (APLA), antithrombin deficiency, protein C and S deficiency, and homozygous genetic thrombophilias or combined defects are at higher risk of recurrence and it is recommended that they receive long-term anticoagulation. If the proportion of patients with "potent" thrombophilia is high then thrombophilia testing should be conducted. We sought to determine the proportion of unprovoked VTE patients with "potent" thrombophilia. Methods All patients with managed in our oral anticoagulation management system in the period from 1998 to 2015 were potentially eligible for the study. Inclusion criteria were: 1) symptomatic, objectively confirmed VTE unprovoked proximal deep vein thrombosis or pulmonary embolism. Exclusion criteria were: 1) cancer or myeloproliferative disease at the time of VTE diagnosis; 2) no cast, surgery, trauma or immobilization (>3 days in bed 90% of waking hours) in the 90 days prior to diagnosis. We selected unprovoked VTE patients diagnosed between 2002 and 2010, as thrombophilia testing was relatively universal and available in our electronic system in that time frame (N=1344). We then selected a convenience sample of N=1165. The primary outcome measure was the proportion of patients with "potent" thrombophilia (potent= homozygous Factor V Leiden, homozygous Prothrombin gene variant, APLA, protein C, protein S or anti-thrombin deficiency or combined deficiencies). Results In 1165 patients with unprovoked VTE, complete screening was done in 470 patients (40.34%) and 976 (83.78%) had at least one thrombophilia test. Complete thrombophilia testing was defined as a screen including testing for factor V Leiden, prothrombin gene defect, APLA, anti-thrombin deficiency, protein C, and protein S. Potent thrombophilias were demonstrated in 103/1165 patients (8.84%; 95% CI, 7.34 to 10.61) (Table 2) in the total study population, and 103/976 (10.55%; 95% CI, 9.62-14.47) in patients with at least one thrombophilia test. Conclusion The proportion of unprovoked VTE patients with "potent" thrombophilia is high. Given a high proportion of "potent' thrombophilia patients who likely benefit from indefinite anticoagulation, complete thrombophilia testing appears warranted in patients with unprovoked VTE in whom anticoagulants maybe discontinued. Thrombophilia testing is warranted for a selected group of patients to detect high-risk thrombophilias that could impact anticoagulation management. Table 1. Thrombophilia screening Complete screening 470 (40.3%) No screening 189 (16.2%) At least one thrombophilia test 976 (83.8%) Table 2. Thrombophilia All patients (n=1165) Tested for individual thrombophilia % 95% CI % 95% CI FVL Heterozygous 162/1165 (13.9%) 12.0-16.0% 162/883 (18.4%) 15.9-21.0% FVL Homozygous 4/1165 (0.3%) 0.1-0.9% 4/883 (0.5%) 0.2-1.2% Prothrombin Heterozygous 63/1165 (5.4%) 4.3-6.9% 63/831 (7.6%) 6.0-9.6% Prothrombin Homozygous 1/1165 (0.0%) 0.0-0.5% 1/831 (0.1%) 0.0-0.7% Antithrombin deficiency 10/1165 (0.9%) 0.5-1.6% 10/815 (1.2%) 0.7-2.2% Protein C deficiency 18/1165 (1.6%) 1.0-2.4% 18/639 (2.8%) 1.8-4.4% Protein S deficiency 13/1165 (1.1%) 0.7-1.9% 13/635 (2.1%) 1.2-3.5% Lupus anticoagulant 24/1165 (2.1%) 1.4-3.1% 24/849 (2.8%) 1.9-4.2% Anticardiolipin IgM 16/1165 (1.4%) 0.9-2.2% 16/886 (1.8%) 1.1-2.9% Anticardiolipin IgG 20/1165 (1.7%) 1.1-2.6% 20/885 (2.2%) 1.5-3.5% β-2 microglobulin IgM 10/1165 (0.9%) 0.5-1.6% 10/333 (3.0%) 1.6-5.4% β-2 microglobulin IgG 8/1165 (0.7%) 0.4-1.4% 8/333 (2.4%) 1.2-4.7% Homocysteine 50/1165 (5.7%) 4.3-7.4% 50/668 (7.5%) 5.7-9.7% Factor VIII elevated 11/1165 (0.9%) 0.5-1.7% 11/646 (1.7%) 1.0-3.0% At least one or more of the above 331/1165 (28.4%) 25.9-31.1% 331/976 (33.9%) 31.0-36.9% Potent thrombophilia 103/1165 (8.8%) 7.34-10.6% 103/976 (10.6%) 9.6-14.5% Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.
30
Kim, Young Sook, Kyoung Soo Jang, and Jung Sup Choi. "Culture optimization of Streptomyces sp. KRA16-334 for increased yield of new herbicide 334-W4." PLOS ONE 19, no. 4 (April 9, 2024): e0301104. http://dx.doi.org/10.1371/journal.pone.0301104.
Abstract:
This study aimed to isolate actinomycetes that exhibit strong herbicidal activity, identify compounds active against weeds, and researching methods to improve the production of these compounds through culture optimization to establish a foundation for the development of environmentally friendly bioherbicides. 334-W4, one of the herbicidal active substances isolated from the culture broth of Streptomyces sp. KRA16-334, exhibited herbicidal activity against various weeds. The molecular formula of 334-W4 was determined to be C16H26N2O6, based on ESI-MS (m/z) and 1H and 13C NMR spectral data. It had molecular weight 365.1689 [M+Na] and 343.1869 [M+H], indicating the presence of the epoxy-β-aminoketone moiety based on HMBC correlations. Additionally, selective culture was possible depending on the addition of trifluoroacetic acid (TFA) during culture with GSS medium. Experiments confirmed that exposure of the KRA16-334 strain to UV irradiation (254 nm, height 17 cm) for 45 seconds improved the yield of the active substance (334-W4) by over 200%. As a result of examining yields of active materials of four mutants selected through optimization of culture conditions such as temperature, agitation, and initial pH, the yield of one mutant 0723–8 was 264.7 ± 12.82 mg/L, which was 2.8-fold higher than that of wild-type KRA16-334 at 92.8 ± 5.48 mg/L.
31
COYNE, MICHAEL. "Lee Clark Mitchell, Westerns: Making the Man in Fiction and Film (Chicago and London, University of Chicago Press, 1996, £23.95). Pp. 331. ISBN 0 226 53234 8." Journal of American Studies 32, no. 2 (August 1998): 307–72. http://dx.doi.org/10.1017/s0021875898495938.
32
Шилова, Елена Романовна, Н. А. Романенко, Д. А. Чебыкина, Т. В. Глазанова, М. Н. Зенина, И. Е. Павлова, and С. С. Бессмельцев. "Long-Term Outcomes of Immunosuppressive Therapy for Aplastic Anemia: A Single-Center Experience." Клиническая онкогематология 16, no. 3 (March 3, 2023): 321–30. http://dx.doi.org/10.21320/2500-2139-2023-16-3-321-330.
Abstract:
Background. Bone marrow transplantation-ineligible aplastic anemia (AA) is most effectively treated with combined immunosuppressive therapy (IST). It yields remissions in most patients. However, it has such disadvantages as frequent relapses, incomplete hematologic recovery, and clonal evolution risk. Besides, АА is not always treated according to standard regimens. For different reasons, some AA patients receive delayed therapy or IST mono-treatment predominantly with cyclosporine A (CsA).
Aim. To assess long-term IST outcomes in AA patients followed-up at the Russian Research Institute of Hematology and Transfusiology for 5 years after therapy onset.
Materials & Methods. The study enrolled 30 AA patients who received IST for more than 5 years (continuous follow-up of 5.5–33 years) with monitoring of the main hemogram parameters and PNH clone size. Patients were aged 19–73 years (median 29 years). There were 8 women and 12 men. Based on international criteria, severe AA (SAA) was initially diagnosed in 18 patients, and non-severe АА (NAA) was diagnosed in 12 patients. Combined IST was administered to 22 patients (18 SAA patients and 4 NAA patients), the remaining 8 patients received ATG (n = 1) and CsA (n = 7).
Results. A response to IST was achieved in 28 (93.3 %) out of 30 patients, 16 (53.3 %) of them showed complete remission. This paper documents the characteristics of hematologic recovery depending on the compliance with standard therapy regimens, as well as on the disease variant, development of late complications and clonal evolution, characteristics of pregnancy and childbirth in 4 female patients in remission. PNH clone increased in more than a half (10 out of 16) patients whose clone was initially > 2.6 %. Long-term clonal evolution to myeloid neoplasia (13 years after IST onset) was registered in 2 (6.7 %) patients with complete AA remission. Aseptic (avascular) osteonecrosis as complication was reported in 6 (20 %) followed-up patients.
Conclusion. The results of the study highlight the importance of and the need for early start and adherence to standard combined IST regimens aimed at optimum therapeutic effect in both SAA and NAA patients, as well as for long-term follow-up of patients after completing IST.
33
Дикарев, Николай Иванович, Борис Михайлович Шабанов, and Александр Сергеевич Шмелёв. "Fine-grained parallelism and higher core performance: advantages of vector dataflow processor." Program Systems: Theory and Applications 10, no. 4 (December 30, 2019): 201–17. http://dx.doi.org/10.25209/2079-3316-2019-10-4-201-217.
Abstract:
В настоящее время резервы в повышении производительности современных процессоров практически исчерпаны, что проявляется в отсутствии роста, как тактовой частоты, так и числа команд, выполняемых в такт, которые определяют скалярную производительность процессорного ядра. В разрабатываемом векторном процессоре с архитектурой управления потоком данных (векторном потоковом процессоре) производительность процессорного ядра может быть повышена до 256 флоп в такт на ядро, что в 8 раз выше по сравнению с последними процессорами Intel Xeon. Это достигается за счет более высокой доли векторных вычислений. В работе показано, что отношение реальной производительности к пиковой на программах битонной сортировки, умножения матриц и 2D Stencil у векторного потокового процессора выше, чем у лучших процессоров традиционной архитектуры.
34
Morales, Manuel Vallalta, Diego Rueda Gordillo, María Teresa Gomis Mascarell, María del Carmen Mafé Nogueroles, Elena Díaz Guardiola, María Desamparados Marco Lattur, Pedro Martínez Avilés, and Rosa Romana Manrique Blázquez. "337 - ANÁLISIS DE LA MORTALIDAD EN UN HOSPITAL DE ATENCIÓN DE PACIENTES CRÓNICOS Y LARGA ESTANCIA (HACLE)." Revista Clínica Española 223 (November 2023): S455—S456. http://dx.doi.org/10.1016/s0014-2565(23)00659-8.
35
Martín, Carlos Hernando, Victoria Pardo Gutiérrez, Carmen de la Higuera Arranz, Cristina Sainz de la Torre, Silvia de Lózar Ortega, Carlos Andrés Martínez Rodríguez, Raúl Rodríguez Galindo, Mario del Valle Sánchez, Carlos Pérez Fernández, and Luis Arribas Pérez. "334 - BACTERIEMIAS DETECTADAS EN EL HOSPITAL SANTOS REYES EN 2022. DATOS EPIDEMIOLÓGICOS Y DE SUPERVIVENCIA. ASESORAMIENTO PROA." Revista Clínica Española 223 (November 2023): S708—S709. http://dx.doi.org/10.1016/s0014-2565(23)00912-8.
36
Pinato, David James, Ahmed Omar Kaseb, Yinghong Wang, Anwaar Saeed, David Szafron, Tomi Jun, Abdul Rafeh Naqash, et al. "Impact of baseline and concomitant corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy." Journal of Clinical Oncology 38, no. 4_suppl (February 1, 2020): 531. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.531.
Abstract:
531 Background: The impact of corticosteroid treatment (CT) on the efficacy of immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC) is undefined. We evaluated whether CT administered at baseline (bCT) or concurrently to ICI (cCT) influences clinical outcomes of HCC patients treated with ICI. Methods: This retrospective, multi-center observational study was conducted across 9 tertiary academic referral centers collected 341 HCC patients who received ICI across 3 continents between January 1, 2016 and April 1, 2019. Outcome measures included overall (OS) and progression-free survival (PFS) calculated from time of ICI commencement and overall response rates (ORR) defined by Response Evaluation Criteria in Solid Tumors (v1.1) on 6-8 weekly periodic restaging. Results: Of 331 eligible patients, 254 (76%) had BCLC-C stage HCC and received mostly PD(L)-1 ICI monotherapy (n=250, 85%). Median OS was 12.1 months (95%CI 9.2-15.0 months) and median PFS was 8.1 months (95%CI 6.3-10 months). In total 81 patients (24%) received >10 mg prednisone equivalent daily either as bCT (n=15, 4%) or cCT (n=66, 20%). Indications for CT included procedure/prophylaxis (n=37, 45%), management of irAE (n=31, 37%), cancer-related symptoms (n=5, 2%) or comorbidities (n=8, 3%). Neither overall CT, bCT nor cCT predicted for worse OS, PFS nor ORR in uni- and multi-variable analyses (p>0.05). CT for cancer-related indications predicted for shorter PFS (2.4 vs. 11.3 months, p=0.01), OS (4.5 vs. 12.8 months, p=0.05) and reduced ORR (p=0.03) compared to cancer-unrelated indications. Conclusions: This is the first study to demonstrate that neither bCT nor cCT appear to influence response and OS following ICI in HCC. Worse survival and ORR in CT recipients for cancer-related indications appears driven by the poor prognosis associated with symptomatic HCC.
37
Stein, T. P., M. D. Schluter, and L. L. Moldawer. "Endocrine relationships during human spaceflight." American Journal of Physiology-Endocrinology and Metabolism 276, no. 1 (January 1, 1999): E155—E162. http://dx.doi.org/10.1152/ajpendo.1999.276.1.e155.
Abstract:
Human spaceflight is associated with a chronic loss of protein from muscle. The objective of this study was to determine whether changes in urinary hormone excretion could identify a hormonal role for this loss. Urine samples were collected from the crews of two Life Sciences Space Shuttle missions before and during spaceflight. Data are means ± SE with the number of subjects in parentheses. The first value is the mean preflight measurement, and the second value is the mean inflight measurement. Adrenocorticotropic hormone (ACTH) [27.7 ± 4.4 (9) vs. 25.1 ± 3.4 (9) ng/day], growth hormone [724 ± 251 (9) vs. 710 ± 206 (9) ng/day], insulin-like growth factor I [6.81 ± 0.62 vs. 6.04 ± 0.51 (8) nM/day], and C-peptide [44.9 ± 8.3 (9) vs. 50.7 ± 10.3 (9) μg/day] were unchanged with spaceflight. In contrast, free 3,5,3′-triiodothyronine [791 ± 159 (9) vs. 371 ± 41 (9) pg/day, P < 0.05], prostaglandin E2(PGE2) [1,064 ± 391 (8) vs. 465 ± 146 (8) ng/day, P < 0.05], and its metabolite PGE-M [1,015 ± 98 (9) vs. 678 ± 105 (9) ng/day, P < 0.05] were decreased inflight. The urinary excretion of most hormones returned to their preflight levels during the postflight period, with the exception of ACTH [47.5 ± 10.3 (9) ng/day], PGE2 [1,433 ± 327 (8) ng/day], PGF2α, [2,786 ± 313 (8) ng/day], and its metabolite PGF-M [4,814 ± 402 (9) ng/day], which were all increased compared with the preflight measurement ( P < 0.05). There was a trend for urinary cortisol to be elevated inflight [55.3 ± 5.9 (9) vs. 72.5 ± 11.1 μg/day, P = 0.27] and postflight [82.7 ± 8.6 (8) μg/day, P = 0.13]. The inflight human data support ground-based in vitro work showing that prostaglandins have a major role in modulating the changes in muscle protein content in response to tension or the lack thereof.
38
McDermott, D. F., C. G. Drake, M. Sznol, J. A. Sosman, D. C. Smith, J. D. Powderly, D. M. Feltquate, G. Kollia, A. K. Gupta, and J. Wigginton. "A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies." Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 331. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.331.
Abstract:
331 Background: Programmed death-1 (PD-1), a T-cell inhibitory receptor, may suppress antitumor immunity. BMS-936558, a fully human PD-1 blocking antibody, has shown antitumor activity and manageable toxicity after biweekly dosing (Sznol, ASCO 2010, #2506). This report provides an update on safety and antitumor activity with special emphasis on RCC. Methods: An open-label phase I dose escalation study of BMS-936558 was conducted in patients (pts) with treatment refractory metastatic clear-cell renal cell carcinoma (RCC), castrate-resistant prostate cancer (CRPC), melanoma (MEL), non-small cell lung cancer, or colorectal cancer (CRC). Dose escalation continued to 10 mg/kg when an expansion cohort for pts (16) with each tumor type was opened for additional safety and efficacy information. Tumor response (RECIST) was evaluated every 8 weeks. Clinically stable pts with early PD could continue until further PD or clinical deterioration. Results: 126 pts (18 RCC) were treated with 1, 3, or 10 mg/kg. MTD was not reached. Across all doses, the most common AEs (Any/grade 3-4) were fatigue (45.2%/6.3%) and diarrhea (30.2%/0.8%) while the most common drug-related AEs (Any/grade 3-4) were fatigue (20.6%/0.8%), rash (11.9%/0%), pruritus (11.3%/0%), and diarrhea (10.3%/0.8%). There was no apparent relationship between dose and frequency of AEs. One pt died with sepsis while being treated for drug-related grade 4 pneumonitis. The median number of prior treatment regimens in the RCC cohort was 2 (range 1-6). Of the 18 RCC pts, 16 were treated with 10 mg/kg. The median duration of treatment was 7.6+mo. ORR was 5/16 (31.2%) and SD>4mo was 6/16 (37.5%). The median duration of response was 4.0+ mo (3.7-7.4+ mo). Of the 2 RCC pts treated with 1 mg/kg, 1 obtained a CR (12+ mo) and 1 had SD (21+ mo). For evaluable CRPC pts, 1/15 pts (6.7%) obtained a PR (2+ mo) and 3/15 (20%) had SD>4mo. Conclusions: BMS-936558 administered biweekly is tolerable and has encouraging antitumor activity in a previously treated patients with RCC. Data on baseline characteristics, long-term toxicity and response duration will be updated at the meeting. [Table: see text]
39
Torner, H., N. Ghanem, C. Ambros, M. Hoelker, W. Tomek, C. Phatsara, H. Alm, et al. "254 MOLECULAR AND SUBCELLULAR CHARACTERIZATION OF OOCYTES SCREENED FOR THEIR DEVELOPMENTAL COMPETENCE BASED ON G6PDH ACTIVITY." Reproduction, Fertility and Development 20, no. 1 (2008): 207. http://dx.doi.org/10.1071/rdv20n1ab254.
Abstract:
Oocyte selection based on glucose-6-phosphate dehydrogenase (G6PDH) activity has been successfully used to differentiate between competent and incompetent bovine oocytes (Alm 2005 Theriogenology 63, 2194–2205). However, the intrinsic molecular and subcellular characteristics of these oocytes have not yet been investigated. Here we aim to compare the developmental, molecular, and subcellular characteristics of oocytes selected using brilliant cresyl blue (BCB) staining based on G6PDH activity. Immature compact cumulus–oocyte complexes (COCs) were stained with 26 µm BCB (B-5388, Sigma-Alderich, Taufenkirchen, Germany) for 90 min. Based on their coloration, oocytes were divided into BCB– (colorless cytoplasm, high G6PDH activity) and BCB+ (colored cytoplasm, low G6PDH activity). The chromatin configuration and the mitochondrial activity of oocytes were determined by fluorescence labelling and photometric measurement (n = 337). The abundance and phosphorylation pattern of protein kinases Akt and MAP kinase were estimated by western blot analysis (n = 500). A bovine cDNA microarray with 2000 clones was used to analyze the gene expression profiles of BCB+ and BCB– oocytes (n = 580). BCB+ oocytes were found to result in a higher blastocyst rate (33.1 � 3.1%) until Day 8 of in vitro culture compared to BCB– ones (12.1 � 1.5%). Moreover, BCB+ oocytes showed higher phosphorylation levels of Akt and MAP kinase compared to the BCB– oocytes. After array data analysis, BCB+ oocytes were found to be enriched with genes regulating transcription (SMARCA5), cell cycle (NASP), and protein biosynthesis (RPS274A and EEF1A1), while the BCB– oocytes had a higher level of genes involved in ATP synthesis (ATP5A1), mitochondrial electron transport (FL405), calcium ion binding (S100A10), and growth factor activity (BMP-15). Independent real-time quantitative PCR validated 90% (9/10) of the genes investigated to be in agreement with the array expression profile. The study has shown evidence of differences in molecular and subcellular organization of oocytes with different G6PDH activity.
40
Nariai, Tadashi, Joseph J. DeGeorge, Nigel H. Greig, and Stanley I. Rapoport. "In vivo incorporation of [9,10-3H]-palmitate into a rat metastatic brain-tumor model." Journal of Neurosurgery 74, no. 4 (April 1991): 643–49. http://dx.doi.org/10.3171/jns.1991.74.4.0643.
Abstract:
✓ Lipid metabolism of an intracerebrally implanted brain tumor and normal brain was investigated in awake Fischer 344 rats using intravenously injected [9, 10-3H]-palmitate as a probe. A suspension of Walker 256 carcinosarcoma cells (250 cells in 5 µl medium), with or without 1 % low-melting-point agar, was implanted into the caudate nucleus of rats 8 to 9 weeks old. Control animals received an intracerebral injection without tumor cells. Seven days after implantation, awake rats were infused intravenously for 5 minutes with [9, 10-3H]-palmitate (6.4 mCi/kg). The rats were killed 20 minutes after initiation of the infusion and coronal brain slices were obtained for quantitative autoradiography and light histological study. Tumor cell masses were histologically well demarcated from the surrounding brain tissue. Tumor tissue incorporation of [9, 10-3H]- palmitate was heterogeneous, ranging on average from 3.1- to 6.1-fold greater than in the corresponding contralateral brain. In addition, incorporation corresponded to regional tumor cell density. The incorporation rate constant of [9, 10-3H]-palmitate in tumor was significantly increased compared to control brain and was independent of tumor size. Necrotic areas within tumors showed no incorporation of radiolabeled palmitate. Brain surrounding the tumors and control injection sites showed reactive gliosis, and possessed 30% greater incorporation of [9, 10-3H]-palmitate than contralateral normal brain. These results suggest that [9, 10-3H]- palmitate can be used to image brain tumors in vivo, measuring turnover and/or synthesis of tumor and brain lipid.
41
Bezerra, Ilana Nogueira, Nila Mara Smith Galvão Bahamonde, Dirce Maria Lobo Marchioni, Dóra Chor, Letícia de Oliveira Cardoso, Estela ML Aquino, Maria da Conceição Chagas de Almeida, Maria del Carmen Bisi Molina, Maria de Jesus Mendes da Fonseca, and Sheila Maria Alvim de Matos. "Generational differences in dietary pattern among Brazilian adults born between 1934 and 1975: a latent class analysis." Public Health Nutrition 21, no. 16 (August 8, 2018): 2929–40. http://dx.doi.org/10.1017/s136898001800191x.
Abstract:
AbstractObjectiveTo identify generational differences in the dietary patterns of Brazilian adults born between 1934 and 1975.DesignA cross-sectional study from the baseline of the multicentre Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohort. Year of birth was categorized into three birth generations: Traditionalists (born between 1934 and 1945); Baby Boomers (born between 1946 and 1964); and Generation X (born between 1965 and 1975). Food consumption was investigated using an FFQ. Latent class analysis (LCA) was used to identify data-driven dietary patterns.SettingBrazil.SubjectsIndividuals (n 15 069) aged 35–74 years.ResultsA three-class model was generated from the LCA for each birth generation. Generation X presented higher energy intakes (kJ/kcal) from soft drinks (377·4/90·2) and sweets (1262·3/301·7) and lower energy intakes from fruit (1502·5/359·1) and vegetables (311·3/74·4) than Baby Boomers (283·7/67·8, 1047·7/250·4, 1756·0/419·7 and 365·3/87·3, respectively) and Traditionalists (186·2/44·5, 518·8/124·0, 1947·7/465·5 and 404·6/96·7, respectively). For Baby Boomers and Generation X, we found food patterns with similar structures: mixed pattern (22·7 and 29·7 %, respectively), prudent pattern (43·5 and 34·9 %, respectively) and processed pattern (33·8 and 35·4 %, respectively). Among Traditionalists, we could also identify mixed (30·9 %) and prudent (21·8 %) patterns, and a third pattern, named restricted dietary pattern (47·3 %).ConclusionsThe younger generation presented higher frequencies of consuming a pattern characterized by a low nutritional diet, compared with other generations, indicating that they may age with a greater burden of chronic diseases. It is important to develop public health interventions promoting healthy foods, focusing on the youngest generations.
42
Hunt, E. D. "R. M. Grant, Greek apologists of the second century. London: S.C.M. Press, 1988. Pp. 254, 8 figs. ISBN 0-334-00535-3." Journal of Roman Studies 80 (November 1990): 241. http://dx.doi.org/10.2307/300331.
43
Lin, Chia-Chi, Tom Wei-Wu Chen, Her-Shyong Shiah, Kien Thiam Tan, Chien-Ting Lin, Tzu-An Hsu, Meng-Chieh Lin, et al. "Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor, in patients with advanced solid tumors." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): e15137-e15137. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e15137.
Abstract:
e15137 Background: ABT-301 (previously known as MPT0E028) is a novel, oral pan-histone deacetylases (HDAC) inhibitor with potent inhibitory activity for HDAC 1, 2, 3 (class I), HDAC 6, 10 (class IIb), modest activity for HDAC 8 (class I) and HDAC 11 (class IV), but no activity for HDAC 4, 5, 7, 9 (class IIa). Preclinical studies showed that ABT-301 had a stronger apoptotic activity and inhibited HDAC activity more potently than vorinostat. ABT-301 exerts antitumor activity as a monotherapy in human colorectal cancer and B-cell lymphoma xenografts and synergistic antitumor activity with immune checkpoint inhibitor in CT26 syngeneic tumor model. Methods: This was a 3+3 Phase 1 dose escalation study to determine the safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and pharmacokinetic (PK) /pharmacodynamic (PD) profiles for the ABT-301 in patients with locally advanced or metastatic solid cancers. 5 cohorts of 3 or 6 patients received ABT-301 once daily at gradually escalating doses starting from 50 mg. Results: 23 subjects (6 sarcomas and 17 carcinomas) were treated at 5 dose levels (3 at 50, 100, and 250 mg respectively, 6 at 150 mg, and 8 at 200 mg). Cycle 1 DLTs occurred in 5 subjects: 1 at 50 mg (G3 mucositis); 2 at 200 mg (G3 abdominal pain and G4 thrombocytopenia); 2 at 250 mg (G3 vomiting and G4 thrombocytopenia). The MTD was 150 mg. The most common treatment-related adverse events were thrombocytopenia (44%), anemia (18%), nausea (61%), vomiting (44%), anorexia (22%), hyperglycemia (22%), fatigue (18%), and mucositis (18%), which were generally G1 to G2 in severity. No cardiac abnormalities were observed. 1 had a partial response (PR), and 8 achieved SD, resulting in a disease control rate (DCR) of 39%. The PR (a patient with eccrine ductal carcinoma) lasted 24 weeks whereas 5/8 SD patients achieved a sustained condition of 16 to 53 weeks (hepatocellular carcinoma, 53 w; thymic cancer, 49 w; salivary gland carcinoma, 27 w; endometrial stromal carcinoma, 25 w; renal cell carcinoma, 16 w). DCR for 9 patients at MTD was 78% (7/9; 1 PR and 6 SD). Plasma PK showed a dose-dependent increase in ABT-301 exposure. Cmax is 5.5 µM and AUC0-inf is 11.5 µM*h at 150 mg. Increased acetylated histone 3 was observed across all cohorts. Conclusions: ABT-301 was well-tolerated at a daily dose of up to 150 mg and demonstrated objective responses and long-term SD across multiple tumor types at MTD. The safety profile of ABT-301 was superior to known HDAC inhibitors with only predictable HDAC inhibitor-related toxicities observed but no cardiac toxicity, neutropenia, nor lymphopenia elicited. Non-clinical and clinical results suggested the potential clinical development of ABT-301 in combination with myelosuppressive agents and immunotherapies. Phase 2 studies combining PD-1/PD-L1 blockade are being designed. Clinical trial information: NCT02350868 .
44
Buresti, Giuliana, Bruna Maria Rondinone, Fabio Boccuni, Antonio Valenti, Carlo Monti, Sergio Iavicoli, and Benedetta Persechino. "O-338 THE SECOND ITALIAN CROSS-SECTIONAL SURVEY ON OCCUPATIONAL SAFETY AND HEALTH: RESULTS FROM A SAMPLE OF IMMIGRANT WORKERS." Occupational Medicine 74, Supplement_1 (July 1, 2024): 0. http://dx.doi.org/10.1093/occmed/kqae023.1274.
Abstract:
Abstract Introduction Work is the main driver of international migration. In 2022 there were about 5 million foreign citizens living in Italy; working age were over 3 million and around 2 million were employed, mainly in agriculture, construction and personal services. Legislative Decree 81/08 calls for specific attention to “workers from other countries”, both in the risk assessment process and in training activities, due to their vulnerability. INAIL conducted the Insula surveys (2014, 2019) aimed at investigating Occupational Safety and Health (OSH) perceptions, emerging risks and levels of awareness of legislation on a large sample of workers, including also foreign workers. Methods The sample consisted of 206 foreign workers extracted from 2019 Insula dataset. Questionnaire was administered using Computer-Assisted Telephone Interviewing (CATI) methodology and consisted of closed-ended questions organized in 8 sections. Results 60% are male and 36% come from EU countries, mainly Eastern Europe; 56% live in Northern Italy. Around 65% of the sample is aware of Italian OSH legislation and 45% attended training courses on OSH issues. 81% believe having legal obligations for OSH and 76% are able to fulfill them. Furthermore, on a 1-5 scale they feel mostly exposed to biomechanical and ergonomic risk (2.6), work-related stress (2.4) and physical risks (2.2). Discussion The inclusion of foreign workers in the survey allows us to gather useful information through the analysis of risk perception of this group of workers. Conclusion Deeper analysis will contribute to better identify needs in the OSH protection to implement preventive instruments, in consideration of peculiarities with reference to their vulnerability.
45
Somerville, M., P. S. Richardson, A. Rutman, R. Wilson, and P. J. Cole. "Stimulation of secretion into human and feline airways by Pseudomonas aeruginosa proteases." Journal of Applied Physiology 70, no. 5 (May 1, 1991): 2259–67. http://dx.doi.org/10.1152/jappl.1991.70.5.2259.
Abstract:
We have investigated the effect of elastase and alkaline protease from Pseudomonas aeruginosa on airway secretion into the trachea of anesthetized cats and from human bronchial mucosa in vitro. Secretory macromolecules were radiolabeled biosynthetically with two precursors in the cat, [3H]glucose and [35S]sulfate, and with [35S]-sulfate only in human tissue. Both enzymes (2.6 x 10(-9) to 1.3 x 10(-6)M elastase and 8 x 10(-9) to 2.4 x 10(-6)M alkaline protease) released radiolabeled macromolecules in a concentration-dependent manner from the two preparations. Purified elastase, 1.3 x 10(-6)M, released radiolabeled macromolecules (delta 3H = +397 +/- 72%, delta 35S 225 +/- 40% over control, P less than 0.001) and periodic acid-Schiff- (PAS) reactive glycoconjugates (delta PAS = +4.1 +/- 0.96 micrograms/min or +102 +/- 20%; P less than 0.01) from cat trachea, as did alkaline protease, 2.4 x 10(-6)M (delta 3H = +356 +/- 57%, delta 35S = +176 +/- 25%, delta PAS = +7.5 +/- 1.3 micrograms/min or 194 +/- 36%, P less than 0.001). Increases in 3H exceeded those of 35S, suggesting surface epithelium as the main source of secretion. Inhibition of enzyme activity abolished secretory effects. Both enzymes also stimulated secretion from human bronchus (e.g., with elastase, 1.3 x 10(-6)M: delta 35S = +331 +/- 67%, delta PAS = +4.3 +/- 0.92 micrograms/min or +131 +/- 24%, P less than 0.001; with alkaline protease, 2.4 x 10(-6)M: delta 35S = +220 +/- 67%, delta PAS = +12.7 +/- 3.2 micrograms/min or +575 +/- 245%, P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
46
Besford, R. T., B. Thomas, N. S. Huskisson, and G. W. Butcher. "Characterization of Conformers of D 1 of Photosystem II Using Site-Directed Antibodies." Zeitschrift für Naturforschung C 45, no. 6 (June 1, 1990): 621–26. http://dx.doi.org/10.1515/znc-1990-0610.
Abstract:
Abstract Antibodies have been raised to synthetic peptides, corresponding to a region in the loop spanning helices 4 and 5 of D 1 protein (Ala 250-Phe 265) and to a region anticipated to be near the C terminus of mature D 1 (His 332-Ala 345). Polyclonal antibodies to the sequence His 332-Ala 345 reacted with a 32 kDa polypeptide in thylakoid preparations identified as D 1 from its resistance (pea) or susceptibility (wheat) to lysine-C degradation. A monoclonal antibody to His 332-Ala 345 reacted preferentially with a faster migrating polypeptide in SDS electrophoresis, a putative conformer of D 1. Polyclonal antibodies to the sequence Ala 250- Phe 265 also reacted with the faster running polypeptide but not with the population of molecules running at 32 kDa. The putative conformer of D 1 from wheat appears to be more resistant than the main D1 population to lysine-C degradation. Peptide analyses by Takahashi et al. [(1988) FEBS Lett, 240, 6 - 8 ] suggest Asn 335-Ala 344 lies at the processed C terminus. The present report provides immunological confirmation that this sequence is retained in mature D 1.
47
Lezama-García, Karina, Julio Martínez-Burnes, Míriam Marcet-Rius, Angelo Gazzano, Adriana Olmos-Hernández, Patricia Mora-Medina, Adriana Domínguez-Oliva, et al. "Is the Weight of the Newborn Puppy Related to Its Thermal Balance?" Animals 12, no. 24 (December 14, 2022): 3536. http://dx.doi.org/10.3390/ani12243536.
Abstract:
Hypothermia, a factor associated with neonatal mortality, can occur immediately after birth as a protective mechanism to prevent hypoxic damage in neonates, or to reduce the metabolic rate to improve the chances of survival in the first hours of life. The heat interchange through the superficial temperature of animals can be evaluated with infrared thermography (IRT). However, to date, there is no information on thermal windows in puppies. This study aimed to evaluate, with the use of IRT, the microcirculatory alterations in 8 different thermal windows identified at 7 different times in 289 newborn puppies assigned to different groups. Three thermograms were taken from four zones of each puppy: the facial, frontal, right lateral, and left lateral regions. Newborn puppies were grouped in 4 quartiles according to their weight: Q1 (126–226 g) n = 73, Q2 (227–330 g) n = 72, Q3 (331–387 g) n = 74, and Q4 (388–452 g) n = 70. A total of 8 thermal windows were considered at 7 evaluation times from Wet at birth until 24 h after birth (AB). Two-way mixed ANOVA within and between subjects’ design for each thermal window (eight models) was performed. Results revealed a positive correlation between the puppy’s weight and its ability to achieve thermostability in all the evaluated thermal windows. Statistically significant differences (p < 0.0001) between the 4 quartiles (Q1, Q2, Q3, and Q4) were found. The lowest temperatures were recorded when the pups were still wet and the highest at 24 h AB. Thermal windows with the highest temperatures were abdominal (34.234 ± 0.056 °C), thoracic (33.705 ± 0.049 °C), nasal (30.671 ± 0.110 °C), and upper left palpebral (34.066 ± 0.052 °C), while the lowest were thoracic limb brachial biceps (27.534 ± 0.051 °C), thoracic limb elbow (27.141 ± 0.049 °C), thoracic limb metacarpal (27.024 ± 0.062 °C), and femoral pelvic limb (27.654 ± 0.055 °C). Assessing the thermal response in newborn puppies can help identify drastic temperature reductions or deficient thermoregulatory compensation during the first hours of life, preventing the consequences of hypothermia.
48
Varela-Benavides, Ingrid, and Reyes Peña-Santiago. "Description of Crassolabium costaricense sp. n. (Nematoda: Dorylaimida: Dorylaimidae) from Costa Rica." Nematology 20, no. 10 (2018): 1007–14. http://dx.doi.org/10.1163/15685411-00003191.
Abstract:
Summary A new species of Crassolabium, C. costaricense sp. n., collected from natural habitats in Costa Rica, is described and illustrated. The new species is characterised by its body length of 1.26 (1.22-1.30) mm in the female and 1.28 (1.16-1.37) mm in the male, lip region nearly continuous and 13.5 (12.5-14.5) μm broad in the female and 13.1 (12.5-14.0) μm broad in the male, odontostyle 17.3 (15.5-19.0) μm long in the female and 18.1 (17.0-19.0) μm long in the male with the aperture occupying 33-42% its length, neck 302-334 μm long, pharyngeal expansion 120-142 μm long or occupying 40-45% of total neck length, uterus tripartite and 163 (134-176) μm long or 2.6-3.1 times the corresponding body diam., pars refringens vaginae well developed, vulva transverse (V = 57.1 (56.0-58.0)), tail short and rounded in female (17.9 (17.0-19.0 μm) long; c = 70.3 (67.0-72.0); c′ = 0.56 (0.50-0.60)) and more conoid in males (21.6 (17.0-23.0) μm long; c = 60.4 (56.0-77.0); c′ = 0.65 (0.50-0.70)), spicules 47 (44-49) μm long, and presence of 8-10 closely spaced ventromedian supplements with an hiatus. Its molecular (LSU D2-D3) characterisation supports an evolutionary relationship with members of the Dorylaimidae.
49
Yaghoobi, Hamideh, Camelia Rohani, Azam Shirin Abadi Farahani, Mahsa Matbouei, and Maryam Tatari. "Correlation Between Oral and Dental Health Status of Primary School Children and Their Family Quality of Life in Torbat Heydariyeh County in Iran." Open Public Health Journal 12, no. 1 (December 31, 2019): 515–20. http://dx.doi.org/10.2174/1874944501912010515.
Abstract:
Background: Due to little information on Iranian families, this study was conducted to investigate the correlation between the oral-dental health status of primary school children and their Family’s Quality of Life (QoL). Materials and Methods: In this cross-sectional study, the oral-dental health status of 251 primary school children in Torbat Heydariyeh county, Iran, was examined according to decayed, missing, and filled teeth index for primary (dmft) and permanent (DMFT) teeth by a checklist. Their mothers (n=251) responded to the Family Impact Scale (FIS) for the assessment of family’s QoL. Data were analyzed using SPSS version 20 by Poisson and Multiple Linear Regression analyses. Results: Primary dental caries of children at an intermediate level (dmft = 3.4 ± 3.1) and their permanent dental caries at a low level (DMFT = 2.6 ± 2.9) were evaluated. The mean score of families’ QoL was estimated 13±7.5 out of a maximum of 56. Pearson correlation test showed that there was no significant correlation between the FIS and dmft/DMFT index (P > 0.05). Regression models revealed that there was a correlation between mothers' dental visits over the past 8 months with the dmft (p=0.006), the DMFT index (p=0.016) and families’ QoL (p=0.045). Conclusion: Although our study didn't show a correlation between the dental health status of children and family’s QoL, the findings showed that there is still a gap between the goals of the WHO and the dental health status of children in Torbat Heydariyeh county.
50
Xancó, Cristina Gabara, Alma Morancho, Marc Montoya, Antonio Martínez, Carles Zamora, María Ortiz, and Jesús Aibar. "335 - FACTORES CLÍNICOS Y ECOGRÁFICOS ASOCIADOS CON LA TROMBOSIS VENOSA RESIDUAL EN PACIENTES CON TROMBOSIS VENOSA PROFUNDA DE EXTREMIDADES INFERIORES." Revista Clínica Española 223 (November 2023): S174—S175. http://dx.doi.org/10.1016/s0014-2565(23)00378-8.